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ABSTRACT 
 
 
 
 
High serum cholesterol, hypertension and 
obesity are major risk factors for cardio-
vascular diseases. Plant sterols and their 
derivatives have been shown to lower serum 
cholesterol in patients with mild hyperchole-
sterolemia. Mineral nutrients, such as calcium, 
potassium and magnesium, lower blood 
pressure, and especially calcium may also 
have beneficial effects on serum lipids. The 
present series of studies was carried out to 
investigate the effects of a combination of 
dietary plant sterols and mineral nutrients on 
serum lipids and blood pressure in obese 
Zucker rats.  
 
During a high-fat, high-cholesterol diet, a 
combination of natural plant sterols and the 
mineral nutrients calcium, magnesium and 
potassium lowered serum cholesterol levels 
more effectively than the plant sterols or the 
minerals alone. This enhancement effect was 
confined to calcium and magnesium, whereas 
sodium and potassium had no independent 
effects on serum cholesterol. Increased intake 
of dietary calcium and magnesium, both with 
and without potassium, also reduced the 
development of obesity during the four to 
seven week experiments. 
 
Calcium supplementation alone dose-
dependently lowered serum total- and LDL 
cholesterols and raised the HDL to LDL 
cholesterol ratio during both low- and high-fat 
diets. Measurements of serum plant sterols and 
the cholesterol precursors desmosterol and 
lathosterol suggested that, during the low-fat 
diet, both intestinal absorption and endo-
genous synthesis of cholesterol were dose-
dependently increased by dietary calcium 
supplementation. During the high-fat diet, only 
the synthesis of cholesterol appeared to in-
crease. Plant sterols were particularly useful 
during low intake of calcium, and their bene-
ficial effects on serum lipids were further 
enhanced by even a moderate increase in 
dietary calcium intake. High calcium intake 
also markedly reduced the development of 
obesity during a high-fat diet, irrespective of 
the addition of plant sterols. 
 
In a long-term experiment, fortification of 
normal rat food with butter, cholesterol and 
common salt resulted in severe hyperlipid-
emia, hypertension, and death in 12 months, 
apparently due to heart infarctions and kidney 
damage. Addition of plant sterols and 
replacing the sodium chloride in this athero-
genic diet partially with calcium, magnesium 
and potassium salts effectively prevented the 
diet-induced increases in total and LDL 
cholesterols and 24-hour systolic and mean 
blood pressures, and markedly improved 
endothelium-mediated vasorelaxation. The 
combination of plant sterols and minerals also 
protected against cardiovascular and renal 
damage and considerably extended the life 
span of the rats. 
 
Our findings indicate that human-type 
cardiovascular disorders can be induced in 
obese Zucker rats by feeding them a human-
type atherogenic diet. Supplementing this diet 
with the combination of mineral nutrients and 
plant sterols exerts several beneficial effects 
that are not likely to be achieved by plant 
sterols alone, including the control of hyper-
tension and obesity. In particular, dietary 
calcium intake appears to be an important 
regulator of serum cholesterol levels in obese 
Zucker rats. The effects of calcium are dose-
dependent and resemble those of bile-acid 
binding resins. With higher doses and during 
high-fat diets, calcium is also likely to reduce 
the absorption of saturated fatty acids. 
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1 INTRODUCTION 
 
 
 
 
Despite very impressive recent advances in 
coronary risk factor identification and 
modification, heart attack remains the 
most common cause of death in Western 
societies. Major risk or even causative 
factors for heart attack, as well as other 
cardiovascular diseases, are elevated 
blood pressure and serum cholesterol 
levels and obesity (Stamler et al. 1993; 
Verschuren et al. 1995; Must et al. 1999). 
These disorders are often associated with 
insulin resistance and other disturbances in 
carbohydrate metabolism; together they 
comprise the notorious metabolic synd-
rome, also referred to as syndrome X or 
Reaven   syndrome   (Reaven 1993),   and  
 
 
Table 1. The metabolic syndrome 
RISK FACTOR DEFINING LEVEL 
Abdominal obesity  (waist circumference) 
     Men > 40 in (102 cm) 
     Women > 35 in (88 cm) 
Hypertriglyceridemia ≥ 150 mg/dl  
   (1.69 mmol/l) 
Low HDL cholesterol  
     Men < 40 mg/dl  
   (1.04 mmol/l) 
     Women < 50 mg/dl  
   (1.29 mmol/l) 
High blood pressure ≥ 130/85 mmHg 
High fasting glucose ≥ 110 mg/dl  
   (6.1 mmol/l) 
multiply the risk of cardiovascular compli-
cations and death (DeFronzo & Ferrannini 
1991). Clinically, the definition of the 
metabolic syndrome is somewhat contro-
versial, but according to one of the most 
recent guidelines (Adult Treatment Panel 
III 2001), the diagnosis can be made when 
three or more of the risk determinants 
shown in TABLE 1 are present.  
 
The increasing prevalence of the metabolic 
syndrome and related disorders in the 
industrialized populations is an enormous 
challenge to preventive public health 
efforts (Joint National Committee 1997; 
Mokdad et al. 1999; Adult Treatment 
Panel III 2001; Ford et al. 2002). While 
medical treatment of these conditions is 
expensive and the results often un-
satisfactory, increased exercise and certain 
changes in dietary habits would benefit 
almost everyone. Results of recent studies 
and public health policy statements 
emphasize abundant intake of fruits and 
vegetables, as well as fat-free and low-fat 
dairy products with increased intake of 
potassium, magnesium, calcium, fiber, and 
protein (WHO Study Group 1991; Joint 
National Committee 1997; Appel et al. 
1997; Kotchen & McCarron 1998; Krauss 
et al. 2000). They also emphasize reduced 
intake of sodium salts, total fats, saturated 
fats, and cholesterol. Unfortunately, 
population-wide implementation of any 
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effective dietary intervention to combat the 
above-mentioned disorders has proven 
problematic. 
 
Enrichment of salt or other widely used 
food items has been the method of choice 
for a population-wide supplementation of 
iodine, various vitamins, iron and other 
mineral nutrients.  A marked increase in 
the levels of potassium and magnesium in 
a variety of food items has been produced 
by using potassium- and magnesium-
enriched salt alternatives instead of 
common salt (Karppanen 1994; Karppa-
nen & Mervaala 1996). The use of such 
foods produces lowering of elevated blood 
pressure and also other beneficial effects 
both in hypertensive animals and in man 
(Karppanen 1989; Mervaala et al. 1992; 
Geleijnse et al. 1994; Mervaala et al. 
1994; Itoh & Kawasaki 1998; Katz et al. 
1999).  
 
Increased intake of plant sterols is another 
approach to dietary treatment of cardio-
vascular risk factors. The serum 
cholesterol-lowering effect of esterified 
plant sterols and stanols in patients with 
mild hypercholesterolemia is well 
established (Law 2000), and a whole new 
class of margarines and other fat-derived 
products containing these compounds has 
been accepted as part of a healthy 
antiatherogenic diet (Lichtenstein & 
Deckelbaum 2001). However, due to 
reactive increase of cholesterol synthesis in 
the liver, only a mild lowering of serum 
cholesterol by plant sterols is achieved, 
and, if the intake of fat is increased, also 
the risk of obesity will increase.  
 
Recently, the protective effects of dietary 
calcium in osteoporosis and hypertension 
have been widely publicized (Bryant et al. 
1999; McCarron & Reusser 1999); 
however, the possible cholesterol-lowering 
effects of calcium have created much less 
interest. Yet, an accumulating body of 
both experimental and clinical evidence 
since the 1950s indicates that calcium 
supplementation might be an effective, 
safe and economic means of reducing the 
serum levels of harmful lipids (Vitale et al. 
1959; Yacowitz et al. 1965; Renaud et al. 
1983; Denke et al. 1993), possibly even 
obesity (Zemel et al. 2000). 
 
The purpose of the present study was to 
explore in the obese Zucker rat, a model of 
the metabolic syndrome, the possibilities 
of natural plant sterols and the mineral 
nutrients calcium, magnesium and 
potassium in the prevention and treatment 
of hyperlipidemia, hypertension and 
obesity, and study the mechanisms of the 
observed effects. A major focus of this 
study was on the effects of dietary calcium 
on serum lipids. 
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2 REVIEW OF THE LITERATURE 
 
 
 
 
2.1 CALCIUM 
 
Calcium is an essential nutrient, quanti-
tatively the most abundant of the bodys 
minerals and a vital electrolyte. Besides 
structural support, calcium is required for 
critical biological functions like nerve 
conduction, muscle contraction, cell 
adhesiveness, mitosis, and blood coagula-
tion. Inadequate intake of calcium is a 
global problem, especially in aging 
populations, and it has been associated 
with several medical disorders, such as 
osteoporosis, hypertension, colon cancer, 
breast cancer, and kidney stones (for 
review, see Miller & Anderson 1999). 
Based on recent research, increased 
dietary intake of calcium is currently 
recommended for the general population 
to lower the risk of these chronic diseases 
(Krauss et al. 2000; Miller et al. 2001). 
 
 
2.1.1 DIETARY INTAKE AND SOURCES 
OF CALCIUM 
 
The Recommended Dietary Allowance 
(RDA) for calcium has long been 800 
mg/d. Recognition of the many health 
benefits of calcium has led to increases in 
dietary calcium recommendations up to 
1500 mg/d, depending on sex and age 
group (NIH Consensus Panel 1994; 
Bryant et al. 1999). Many population 
groups, however, consume even less than 
the RDA of calcium, especially in the USA 
(Fleming & Heimbach 1994). In Finland, 
the situation is clearly better; the mean 
intake of calcium is 913 mg/d in women 
and 1159 mg/d in men (National Public 
Health Institute 1998), but particularly 
among adolescent and older females 
calcium intake may still be inadequate.  
 
Governmental and health professional 
organizations, as well as leading nutrition 
and medical experts, recommend food as 
the preferred source of calcium (NIH 
Consensus Panel 1994; Miller et al. 2001). 
By far the most important of dietary 
sources of calcium is milk. Milk has a high 
calcium content of 12001300 mg/l, and 
milk and other dairy products provide 
approximately 75% of the total calcium 
available in the food supply (National 
Public Health Institute 1998). Fruits, 
vegetables and cereals also contain 
calcium but to a much lesser extent. 
Hence, people who avoid milk products 
for some reason, such as lactose 
intolerance, may need to consider 
consuming calcium-fortified food items or 
calcium supplements (Miller et al. 2001). 
 
In addition to the content of calcium in 
foods, the bioavailability of calcium from 
foods must be considered (Gueguen & 
Pointillart 2000). It ranges from a low of 
5% in spinach to about 30% in milk and 
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more than 60% in broccoli (Weaver et al. 
1999). However, high absorbability cannot 
overcome a low content: almost five kilos 
of broccoli needs to be consumed to get 
the same amount of calcium absorbed as 
from one liter of milk. The problem with 
most vegetables and cereals is that they 
contain oxalates and phytates, which 
inhibit the absorption of calcium (Weaver 
et al. 1999). On the other hand, 
industrially processed milk products often 
contain excess amounts of phosphates and 
sodium salts (National Public Health 
Institute 1998). Phosphate binds calcium 
in the intestine, and sodium linearly 
increases the excretion of calcium in urine 
(Nordin et al. 1993), even independently 
of calcium intake (Matkovic et al. 1995). 
Urinary calcium losses account for 50% of 
the variability of calcium retention (NIH 
Consensus Panel 1994). Therefore, foods 
with reduced sodium and increased 
calcium contents would appear most 
advantageous. 
 
Calcium can also be obtained from 
commercial supplements. Calcium in 
supplements is found in various forms 
including calcium carbonate, citrate, citrate 
malate, gluconate, and lactate. In general, 
the absorption of calcium from the 
different salts is similar, but carbonate, 
which contains the highest percentage of 
calcium, is usually the least expensive and 
thus most cost-effective (Heaney et al. 
2001). Some supplements may also 
contain vitamin D that helps in calcium 
absorption, and magnesium that as well is 
a vital electrolyte and may become poorly 
absorbed during high calcium intake. 
 
However, what is absorbed is not the only 
important part of the ingested calcium. 
The non-absorbed fraction can bind many 
potentially harmful food ingredients, such 
as oxalic acid and saturated fatty acids, 
and the precipitation of bile acids with 
calcium may even contribute to lowering 
of the risk of atherosclerosis and colorectal 
cancer (see 2.1.3). 
 
 
2.1.2 PHYSIOLOGY OF CALCIUM 
 
An average adult body contains about 1,5 
kg of calcium, 99% of it in the skeleton (for 
review, see Marx 1996). The calcium in 
the bone is in equilibrium with the calcium 
in the extracellular fluid, but only about 
0.5% of the total pool is exchangeable. 
Calcium in blood is divided among 
protein-bound, complexed, and ionized or 
free fractions. The ionized fraction is the 
focus of metabolic control, especially 
through parathyroid hormone (PTH) and 
vitamin D, and it is kept constant at 1.0
1.2 mmol/l by processes that continuously 
add and remove calcium. Calcium enters 
the plasma via absorption from the 
intestine and resorption of from the bone 
mineral. Bone resorption and formation 
are tightly coupled, with approximately 
500 mg of calcium entering and leaving 
the skeleton daily. Calcium leaves the 
extracellular fluid via secretion into the 
gastrointestinal tract, excretion in urine, 
deposition in bone mineral, and secretion 
in sweat.  
 
Generally, less than half of dietary calcium 
is absorbed in adults (for review, see 
Gueguen & Pointillart 2000). Calcium 
absorption increases during growth, 
pregnancy, and lactation, and decreases 
with advancing age. Most of the calcium is 
absorbed in the proximal small intestine, 
and the efficiency of absorption decreases 
in the more distal intestinal segments. 
Active transport is more important in the 
upper intestine, and diffusion-limited 
absorption in the lower intestine. Both 
processes are influenced by vitamin D. 
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Secretion of calcium into the intestinal 
lumen occurs at a constant rate of 
100−200 mg/d and is independent of 
absorption. In all, about 90% of the daily 
intake of calcium is excreted in the feces. 
 
The amount of calcium excreted in the 
urine, about 50−300 mg/d, is normally less 
than 2% of that filtered by the glomerulus. 
This is due to very efficient reabsorption, 
which takes place predominantly in the 
proximal tubule and in Henle's loop and to 
a small extent in the distal tubule (for 
review, see Rouse & Suki 1990). The 
excretion of other electrolytes affects the 
urinary excretion of calcium. For example, 
urinary calcium is usually proportional to 
urinary sodium, and sulfate also increases 
calcium excretion.  
 
The primary regulator of calcium 
metabolism is PTH; it acts directly on 
bone, where it induces calcium resorption, 
and on the kidneys, where it stimulates 
calcium reabsorption and synthesis of 
1,25-dihydroxycholecalciferol, the active 
form of vitamin D that stimulates calcium 
absorption from the gastrointestinal tract 
(for reviews, see Dawson-Hughes 1996 
and Guyton & Hall 1996). Serum PTH 
levels are tightly regulated by a negative 
feedback loop. Calcium, acting through 
the calcium-sensing receptor, and vitamin 
D, acting through its nuclear receptor, 
inhibit PTH synthesis and release. The 
homeostatic action of PTH can preserve 
blood calcium concentration acutely at the 
cost of bone destruction. Immediate 
control of blood calcium is probably due 
to the effects of the hormone on bone and, 
to a lesser extent, on renal calcium 
clearance. Maintenance of steady-state 
calcium balance, on the other hand, 
probably results from the effects of vitamin 
D on calcium absorption. This is mediated 
principally by regulation of the formation 
of a calcium-binding protein in the 
intestinal epithelial cells over a period of 
several days. 
 
 
  
Fig 1. Regulation of calcium balance 
 
 
Calcitonin is another hormone regulating 
calcium homeostasis (Guyton & Hall 
1996). It is secreted by the thyroid gland, 
and in several mammalian species it acts 
as the physiologic antagonist to PTH; 
however, in humans the physiologic 
significance of calcitonin is questionable. 
The hypocalcemic activity of calcitonin is 
accounted for primarily by inhibition of 
osteoclast-mediated bone resorption and 
secondarily by stimulation of renal calcium 
clearance. 
 
The physiology of calcium metabolism is 
also tightly coupled with phosphate 
absorption and excretion (Guyton & Hall 
1996). Normally, when diet contains 
about equal amounts of calcium and 
phosphate, phosphate is partly excreted in 
the feces in combination with non-
absorbed calcium, and the rest is readily 
absorbed into the blood and later excreted 
in the urine. In the kidney, about 8090% 
of phosphate is reabsorbed, mainly in the 
proximal tubules. PTH, by augmenting 
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phosphate excretion via inhibition of this 
proximal reabsorptive process, plays a 
central role in phosphate homeostasis. 
When dietary phosphate intake increases, 
a transient rise in plasma phosphate 
concentration is usually observed. This 
results in a similarly transient reduction in 
the plasma ionized calcium level, due 
largely to deposition of calcium phosphate 
in bone, which stimulates PTH secretion. 
By enhancing fractional phosphate 
excretion, PTH restores external 
phosphate balance and normophosphat-
emia. Vitamin D probably opposes the 
phosphaturic actions of PTH in the renal 
tubules by augmenting phosphate re-
absorption. Hypophosphatemia, on the 
other hand, decreases the rate of calcium 
uptake into bone, increases intestinal 
calcium absorption, and directly and 
indirectly stimulates bone breakdown. 
 
 
2.1.3 CALCIUM AND SERUM LIPIDS 
 
Considering the ever-growing amount of 
calcium-related research, particularly 
around hypertension and osteoporosis, it 
is surprising how little attention has been 
called upon the possible lipid-lowering 
effects of an increased intake of calcium. 
 
Epidemiological evidence in favor of the 
hypothesis of calcium as a lipid-lowering 
agent is undeniably scarce. Higher calcium 
intake rather seems to correlate with 
higher serum cholesterol levels and 
incidence of coronary heart disease (Segall 
1977; Sharlin et al. 1992; Artaud-Wild et 
al. 1993). This might be due to the fact 
that dietary calcium usually comes from 
milk products that often contain lots of 
saturated fat and cholesterol, which may 
override the effects of calcium. Conversely, 
low-fat and low-cholesterol diets, which 
lower serum lipid levels, often contain less 
calcium (Schectman et al. 1990; Holbrook 
& Barrett-Connor 1991). One fairly large 
cross-sectional study in 5 394 men and 4 
800 women found a linear increase of 
both total cholesterol and HDL cholesterol 
with serum calcium levels, independent of 
confounding factors such as age, blood 
pressure, body weight, fat and cholesterol 
intake (De Bacquer et al. 1994). Recently, 
no association between milk consumption 
and coronary or all cause mortality was 
found in a 25-year prospective study on a 
cohort of 5 765 men in Scotland (Ness et 
al. 2001). In a large cohort study of 34 
486 postmenopausal women, higher 
intake of calcium, but not of vitamin D or 
milk products, was associated with 
reduced ischemic heart disease mortality 
(Bostick et al. 1999). On the other hand, 
several studies indicate that milk and milk 
products have hypolipidemic and anti-
atherogenic effects (Howard & Marks 
1977; Pfeuffer & Schrezenmeir 2000), 
which could be related to calcium, but 
may also be due to other bioactive 
substances in milk (Sipola 2002).  
 
However, there are intervention studies 
both with animals (TABLE 2) and humans 
(TABLE 3) that have explored the effects of 
dietary calcium on serum lipids.  
 
In rats supplemented with dietary fat and 
cholesterol (Vitale et al. 1959; Fleischman 
et al. 1967; Yacowitz et al. 1967; 
Fleischman et al. 1972), consistent 
decreases in serum total cholesterol and 
triglycerides with increased calcium intakes 
were observed. The level of serum total 
cholesterol in rats fed 1.2% dietary 
calcium was about 3040% lower and 
with 2.0% calcium up to 60% lower than 
in the controls fed low-calcium diets. 
Calcium was hypolipidemic during both 
saturated and polyunsaturated fat supple-
mentation, but the effects were more 
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Table 2. Effects of dietary calcium on serum lipids in animals 
Species Diet; treatments; duration Results Reference 
Rat  20% fat, 1% cholesterol, 
0.3% cholic acid; [Ca] 0.2, 
0.6 or 1.2%, [Mg] 0.02 or 
0.2%; 4 weeks 
TC ↓  PL ↓  Vitale et al. 1959 
Rat 20% fat, 2% cholesterol; 
[Ca] 0.08, 0.2, 1.2 or 2%;    
5 months 
TC ↓  TG ↓  Fecal fat, bile 
acids and sterols ↑ 
Fleischman et al. 
1967 
Rat 20% fat, 2% cholesterol;  
[Ca] 0.08, 0.2 or 1.2%;        
3 weeks 
TC ↓  TG ↓  Fecal fat, bile 
acids and sterols ↑ 
Yacowitz et al. 1967 
Rat 20% fat, 2% cholesterol;  
[Ca] 2.0 % ± vitamin D2;      
3 weeks 
TC ↓  TG ↓  Fecal fat and 
sterols ↑  
Fleischman et al. 
1972 
Rabbit Low-fat; [Ca] 0.02, 0.8 or 
1.6%; 3 months 
TC ↓  TG ↔  Iacono 1974 
Rabbit 25% butter, 25% casein; 
[Ca] 0.3 or 0.9%, [Mg] 0.04 
or 0.4%; 6 months 
TC ↓  HDL-C ↔  TG ↓  
Atherosclerosis ↓  
Renaud et al. 1983 
Rabbit  10% fat, 21% casein; 
[Ca] 0.8 or 1.4%; 7 weeks 
TC ↓  PL ↔  Fecal fat ↑ Van der Meer et al. 
1985 
Rabbit 11% fat, 20% casein, cod, or 
soy protein; [Ca] 0.7 or 1.4%; 
4 weeks 
TC ↓  LDL-C ↓  HDL-C ↔ 
VLDL-C ↓  TG ↔       
Fecal fat↑ 
Jacques et al. 1995 
Pig 19% fat, 0.05% cholesterol; 
[Ca] 0.7 or 2.1% ± vitamin D; 
6 weeks 
No changes in TC, VLDL-
C, LDL-C, HDL-C, or TG 
Foley et al. 1990 
Pig 
 
10% butter, 0.5% cholesterol; 
[Ca] 0.7 or 1.4%; 15 days 
TC ↓  LDL-C ↓ HDL-C ↔  
Serum bile acids ↓  
De Rodas et al. 1996 
Goat Fat and cholesterol 
supplemented goat milk; 
[Ca] 0.1% or 0.2%; 20 weeks 
No changes in TC, VLDL-
C, LDL-C, HDL-C, or TG 
Diersen-Schade et 
al.1984 
Goat Normal goat milk; 
[Ca] 0.1% or 0.2%  
± vitamin D3; 20 weeks 
TC ↓  Atherogenesis ↓  
Fecal fat ↔ 
Hines et al. 1985 
[Ca] = total calcium content; TC = total cholesterol; VLDL-C, LDL-C, HDL-C = very low, low, 
high density lipoprotein cholesterol; TG = triglycerides; PL = phospholipids 
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pronounced in the presence of saturated 
fat (Yacowitz et al. 1967). Cholic acid 
enhanced the diet-induced hyperlipidemia 
and even abolished the effects of calcium 
(Vitale et al. 1959), but vitamin D had no 
significant effect on either direction 
(Fleischman et al. 1972). In New Zealand 
white rabbits fed a low-fat diet, calcium 
supplementation lowered serum total 
cholesterol and reduced the accumulation 
of cholesterol in heart, kidney and 
muscles, but the tissue triglyceride levels 
were increased (Iacono 1974). In a six-
month experiment with butterfat-
supplemented rabbits, Renaud et al. 
(1983) found that calcium and 
magnesium, in addition to lowering of 
cholesterol and triglycerides, also reduced 
platelet aggregation, the severity of 
atherosclerosis and accumulation of 
cholesterol in the aorta. Casein and cod 
protein -induced hypercholesterolemia in 
rabbits was effectively counteracted by 
1.4% dietary calcium, while soy protein 
did not raise serum lipid levels at all (Van 
der Meer et al. 1985; Jacques et al. 1995). 
In fat- and cholesterol-supplemented pigs 
the effects of calcium were less 
unanimous. Tripling the dietary calcium 
intake had no effect on cholesterol or 
triglyceride concentrations in plasma or 
their partitioning among plasma lipo-
proteins (Foley et al. 1990). The levels of 
both dietary and plasma cholesterol in this 
study, though, were only a fraction of 
those in the other pig study (De Rodas et 
al. 1996), where the lowering of serum 
total and LDL cholesterol after dietary 
cholesterol supplementation was enhanced 
by a diet containing 1.4% calcium. 
Another species where findings seem to 
differ is young goat. Diersen-Schade et al. 
(1984) found no effect of dietary fat or 
calcium on plasma and lipoprotein 
cholesterol concentrations, but a year later 
Hines et al. (1985) reported calcium-
induced lowering of cholesterol in plasma 
and tissues in a similar setting. High intake 
of vitamin D, however, reversed the 
beneficial effects of calcium, resulting in a 
marked increase in lipid accumulation in 
the aorta. 
 
The first clinical studies in the 1960s and 
1970s were rather small but well con-
ducted and showed a consistent serum 
cholesterol- and triglyceride-lowering effect 
of increased dietary calcium intake. In 
healthy adults on normal diets, a moderate 
890 mg/d calcium supplementation 
produced a mean 15.4 mg/dl (0.4 mmol/l) 
decrease in serum total cholesterol and 
32.2 mg/dl (0.83 mmol/l) decrease in 
triglycerides (Yacowitz et al. 1965). The 
decreases were greater, up to 1530% in 
those whose baseline lipid levels were 
elevated. Calcium counteracted the rise of 
serum cholesterol induced by saturated fat; 
polyunsaturated fat supplementation did 
not raise the cholesterol levels 
(Bhattacharyya et al. 1969). In hyper-
lipidemic patients, Carlson et al. (1971) 
found a 10% decrease in serum chole-
sterol during calcium treatment, but no 
change in triglycerides; Bierenbaum et al. 
(1972) reported a calcium-induced 
decrease in all serum lipids over 12 
months; and Lehtonen & Viikari (1979) 
showed that calcium supplementation was 
able to enhance the lipid-lowering effect of 
clofibrate. In children with familial hyper-
cholesterolemia, calcium supplementation 
in addition to a low-fat and low-cholesterol 
diet produced a rather small but significant 
4% decrease in serum LDL cholesterol 
and a 4% increase in serum apolipo-
protein A1, which is the main protein in 
HDL (Groot et al. 1980). Similar results 
were achieved in adults with only 400 
mg/d increase in calcium intake, in 
addition to the low-fat, low-cholesterol diet 
(Bell et al. 1992). Bierenbaum et al. 
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Table 3. Effects of dietary calcium on serum lipids in humans 
Subjects Design, duration Intervention Result Reference 
13 healthy adults Cross-over, 3 weeks Ca 890 mg/d TC ↓  TG ↓   
Fecal fat ↑  
Yacowitz et al. 
1965 
12 healthy men Cross-over,  
4 x 2 weeks 
SAFA/PUFA 
90g+Ca 2 g/d 
TC ↓  Fecal fat 
and C ↑ 
Bhattacharyya 
et al. 1969 
16 HC patients Cross-over with 
placebo, single-blind, 
4+8 weeks 
Ca 2 g/d TC ↓  TG ↔ Carlson et al. 
1971 
20 HC patients Randomized, open, 
12 months 
Ca 800 mg/d TC ↓  TG ↓  Bierenbaum et 
al. 1972 
30 HC patients Cross-over with 
placebo, single-blind, 
16 months 
Clofibrate + 
Ca 800 mg/d 
VLDL-C ↓   LDL-
C ↓  HDL-C ↔  
TG ↔ 
Lehtonen & 
Viikari 1979 
50 FHC children Cross-over with 
placebo, double-
blind, 10+10 weeks 
Ca 400 mg/d LDL-C ↓   
Apo-AI ↑ 
Groot et al. 
1980 
43 hypertensive  
27 normotensive 
Randomized, double-
blind, cross-over, 
8+8 weeks 
Ca 1 g/d  TC, VLDL-C, 
LDL-C, HDL-C, 
and TG: ↔ 
Karanja et al. 
1987 
200 healthy 
adults 
Open, 6 months Ca 1,4 g/d  TC ↓  HDL ↔  
TG ↔ 
Bierenbaum et 
al. 1987 
56 HC patients Randomized, double-
blind, cross-over, 
6+6 weeks 
AHA Step-1 + 
Ca 1,2 g/d 
LDL-C ↓     
HDL-C ↑ 
Bell et al. 
1992 
13 healthy men Randomized, single-
blind, cross-over, 
10+10 days 
Ca 1,8 g/d  TC ↓  LDL-C ↓  
Apo-B ↓  TG ↔ 
HDL-C ↔ Apo-
A1 ↔ Fecal fat↑  
bile acids ↔ 
Denke  et al. 
1993 
130 hypertensive 
196 normotensive 
Randomized, 
parallel, placebo-
controlled, 12 weeks 
Ca 1 g/d TC, VLDL-C, 
LDL-C, HDL-C, 
and TG: ↔ 
Karanja et al. 
1994 
10 healthy men Randomized, double-
blind, cross-over, 
2+2 weeks 
Ca 900 mg/d LDL-C ↓     
HDL-C ↔ TG ↔ 
Fecal fat and 
bile acids ↑ 
Shahkhalili et 
al. 2001 
223 elderly 
women 
Randomized, 
placebo-contr, 1 year 
Ca 1 g/d TC ↔  LDL-C ↓  
HDL-C ↑ TG ↔ 
Reid et al. 
2002 
(F)HC = (familial) hypercholesterolemia; Ca = supplemental elementary calcium;  
SAFA/PUFA = saturated/polyunsaturated fatty acids; C = cholesterol; TC = total cholesterol; 
LDL-C, VLDL-C, HDL-C = low, very low, high density lipoprotein cholesterol;  
Apo = apolipoprotein; TG = triglycerides  
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(1987) had 200 volunteers drink one liter 
of calcium-fortified milk per day for six 
months and reported, in addition to 7/6 
mmHg decrease in blood pressure, a slight 
decrease in serum total cholesterol. Two 
smaller studies have examined the effects 
of dietary calcium fortification on serum 
and fecal lipid contents. Increased intake 
by 1800 mg/d resulted in decreases of 6% 
in total and 11% in LDL cholesterol and 
doubled the saturated fat excretion (Denke 
et al. 1993), and supplementation of 900 
mg/d of calcium in chocolate markedly 
reduced the absorption of cocoa butter, 
and lowered plasma LDL cholesterol by as 
much as 15% (Shahkhalili et al. 2001). 
Very recently, a 1 g/d calcium supplemen-
tation was reported to produce a 7% 
increase in HDL cholesterol and 6% 
decrease in LDL cholesterol in a study on 
223 healthy postmenopausal women  the 
group most commonly using calcium 
supplements (Reid et al. 2002). However, 
not all studies have demonstrated any 
hypolipidemic effects for calcium. Two 
fairly large intervention studies by the 
same group (Karanja et al. 1987; Karanja 
et al. 1994) found that hypertensive 
patients at baseline consumed less 
calcium, magnesium and potassium than 
normotensive patients and had signific-
antly lower HDL cholesterol and higher 
LDL cholesterol levels, but no changes 
occurred in plasma lipids or lipoproteins 
with either calcium supplementation or 
counseling to increase dietary calcium 
intake. 
 
Mechanisms of the effects 
The possible hypolipidemic mechanisms of 
calcium include 1) inhibition of the 
intestinal absorption of cholesterol 
(Fleischman et al. 1967; Yacowitz et al. 
1967; Bhattacharyya et al. 1969; 
Fleischman et al. 1972; Diersen-Schade et 
al. 1984), 2) inhibition of absorption of 
bile acids (Fleischman et al. 1967; 
Yacowitz et al. 1967; De Rodas et al. 
1996; Shahkhalili et al. 2001), and 3) 
inhibition of absorption of fat (Yacowitz et 
al. 1965; Fleischman et al. 1967; Yacowitz 
et al. 1967; Bhattacharyya et al. 1969; 
Fleischman et al. 1972; Van der Meer et 
al. 1985; Denke et al. 1993; Jacques et al. 
1995; Shahkhalili et al. 2001).  
Binding bile acids is a mechanism familiar 
from the effect of cholestyramine and 
other resins (Witztum 1996). The 
catabolism of cholesterol to bile acids is an 
important route for the elimination of 
cholesterol from the body, accounting for 
approximately 50% of the cholesterol 
eliminated daily (St-Pierre et al. 2001). 
Increased fecal loss of bile acids results 
firstly in decreased absorption of fat and 
cholesterol and secondly in increased 
conversion of cholesterol to bile acids in 
the liver. Even if de novo synthesis of 
cholesterol is increased, it may not be 
sufficient for the replacement bile acid 
synthesis, and cholesterol must be taken 
from the circulation via LDL-receptors, 
which leads to lowering of serum LDL 
cholesterol.  
Increased fecal loss of fat, especially 
saturated fat, is also important because 
saturated fatty acids, when absorbed, will 
inhibit the receptor-mediated uptake of 
LDL into liver cells, thereby decreasing the 
clearance of LDL particles from the 
circulation (Kris-Etherton et al. 1988; 
Grundy & Denke 1990). Consequently, 
decreased absorption of saturated fat 
would lead to a decrease in serum 
cholesterol. Calcium and other divalent 
cations may bring about this effect through 
precipitation of saturated fatty acids from 
the solution. This concept of formation of 
non-absorbable calcium and magnesium 
soaps in the intestine was first proposed by 
Givens (1917), and has since been 
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confirmed in both animal and human 
studies (Drenick 1961; Welberg et al. 
1994). The bile and fatty acid binding 
properties of calcium are also utilized in 
the prevention of colorectal neoplasia 
(Baron et al. 1999; Holt 1999). 
 
In summary, despite some controversy 
and lack of large epidemiological and 
intervention studies, the existing evidence 
strongly suggests that calcium does have 
beneficial effects on serum lipids, in 
animals as well as in humans. Larger-scale 
prospective clinical trials need to be 
conducted to define the scope and 
significance of this effect. 
 
 
2.1.4 CALCIUM AND BLOOD PRESSURE 
 
After 20 years of intense investigation in 
the area of dietary calcium and blood 
pressure, a consensus is at hand: a large 
body of recent data consistently and 
clearly prove the antihypertensive effect of 
increased intake of calcium (for review, 
see McCarron & Reusser 1999). The 
association between higher dietary calcium 
intake and lower prevalence of high blood 
pressure was first reported by McCarron et 
al. (1984) in the analysis of the first 
National Health and Nutrition 
Examination Survey (NHANES I). Since 
then, more than 30 well-designed 
epidemiological studies assessing the 
calcium-blood pressure relationship have 
been published. A meta-analysis of 23 
observational studies estimated that each 
100 mg increase in daily calcium intake 
would produce a lowering of 0.39 mmHg 
in systolic and 0.35 mmHg in diastolic 
blood pressure (Birkett 1998). 
 
Studies in various strains of hypertensive 
rats and their normotensive counterparts 
have largely confirmed the initial 
hypothesis that an increase in dietary 
calcium intake reduces blood pressure, 
and provided some insight into its possible 
mechanisms of action (for review, see 
Hatton & McCarron 1994; Schleiffer & 
Gairard 1995). Calcium may act 
concurrently through several physiological 
mechanisms, including reduced 
membrane permeability and intracellular 
calcium, changes in calcium-regulating 
hormones, modulation of the sympathetic 
nervous system, and altering the 
metabolism of other electrolytes (Hatton et 
al. 1995). Pörsti (1991) found that the 
urinary excretion of sodium increased and 
the action of deoxycorticosterone on 
sodium balance was prevented (Pörsti et 
al. 1991), and that the activity of 
erythrocyte cell membrane calcium-
ATPase was increased, platelet intra-
cellular free calcium reduced, vascular 
smooth muscle relaxation improved and 
contractile responses attenuated by a high-
calcium diet in spontaneously hypertensive 
rats (Pörsti et al. 1990; Pörsti 1992). These 
results were later confirmed, and comple-
mented by new observations indicating 
that the augmented endothelium-
dependent vasorelaxation could be ex-
plained by enhanced hyperpolarization, 
mediated via opening of calcium-activated 
potassium channels, increased sensitivity 
to nitric oxide in arterial smooth muscle, 
and decreased production of superoxide 
and vasoconstrictor prostanoids (Mäkynen 
et al. 1996; Tolvanen et al. 1998; Jolma et 
al. 2000).  
 
The antihypertensive effect of increased 
dietary calcium intake may also be 
mediated via suppression of the calci-
trophic hormones PTH and vitamin D 
(Zemel 2001). These hormones increase 
vascular smooth muscle intracellular 
calcium, which leads to increased peri-
pheral resistance and blood pressure 
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(FIGURE 2). Dysregulation of calcium 
homeostasis may also be a fundamental 
factor linking together hypertension and 
obesity (Zemel 2001). 
 
 
More than 60 calcium intervention trials in 
humans have been reported, and as with 
all nutrient modification trials, the results 
have been heterogeneous (Luft & 
McCarron 1991). However, a most 
carefully conducted and recent meta-
analysis of 43 randomized controlled 
studies found that both dietary and 
supplemental increase in calcium intake to 
more than 1000 mg/d for at least two 
weeks leads to a significant reduction in 
blood pressure (Griffith et al. 1999). 
Pooled estimates across all studies, 
comprising 3500 subjects altogether, 
showed decreases of 1.44 mmHg in 
systolic and 0.84 mmHg in diastolic blood 
pressure. The decreases tended to be 
greater and less heterogeneous in dietary 
calcium studies as compared with those 
that employed non-food sources of 
calcium (Griffith et al. 1999). Perhaps the 
most important recent study in this area is 
the Dietary Approaches to Stop 
Hypertension (DASH) trial (Appel et al. 
1997). The DASH diet, rich in calcium, 
magnesium, potassium and fiber, 
produced up to 11.4/5.5 mmHg reduc-
tions in blood pressure and, when 
analyzed statistically for calcium effect, the 
observed reductions in blood pressure 
correspond remarkably with those 
revealed by meta-analyses of both 
epidemiological and clinical intervention 
trials (McCarron & Reusser 1999). On the 
whole, these data support the role of the 
combination of the mineral nutrients as an 
independent factor that significantly 
contributes to the lowering of hypertension 
risk. 
 
  
Fig 2. Suggested mechanism of the effects of 
dietary calcium on blood pressure and obesity 
(Zemel 2001) 
 
 
2.1.5 CALCIUM AND OBESITY 
 
Obesity is the common denominator in 
several comorbid conditions, including 
hypertension, hyperlipidemia and type II 
diabetes, and its prevalence is increasing 
rapidly all over Western world (for review, 
see Anderson & Konz 2001). While it is 
known that weight reduction would be one 
of the most effective means of lowering the 
risk of cardiovascular diseases  even a 
few per cent decrease in body weight is 
associated with significant lowering of 
blood pressure and improvement of 
glucose tolerance and blood lipid profile 
(Anderson & Konz 2001)  the treatment 
of obesity in practice has proven extremely 
difficult.  
 
Reductions in body weight gain were 
observed in several of the previously cited 
experimental calcium supplementation 
studies (Fleischman et al. 1967; Yacowitz 
et al. 1967; Foley et al. 1990; Pörsti et al. 
1990; Mäkynen et al. 1996). There are 
two plausible explanations: dietary calcium 
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may form soaps with fatty acids and 
thereby prevent the absorption of some of 
the fatty acids released during lipid 
digestion, and/or dietary calcium may bind 
bile acids, which would decrease micelle 
formation and thus reduce lipid absorption 
and digestible energy of the diet. Many of 
these studies also reported increases in 
fecal fat excretion, which supports these 
assumptions.  
 
Among the clinical studies addressing the 
effect of calcium on serum lipids, Carlson 
et al. (1971) reported a significant 0.55 kg 
weight loss by calcium supplementation of 
2 g/d for eight weeks, and Karanja et al. 
(1994) found a small but significant 
decrease in body weight by 1 g/d calcium 
supplementation in both men and women 
in 12 weeks. In the same study, counseling 
to increase dietary calcium through food 
consumption to 1.5 g/d resulted in 
substantial increase in energy intake, yet 
body weight was not significantly altered. 
Neither did Shahkhalili et al. (2001) find 
any significant changes in body weight 
during two weeks consumption of 
calcium-fortified chocolate. The other 
studies listed in TABLE 3 did not report 
body weights. In a clinical trial investigat-
ing the antihypertensive effect of calcium 
in obese African-Americans, an increase in 
calcium intake from about 400 to 1000 
mg/d for one year resulted in as much as 
4.9 kg reduction in body fat (Zemel et al. 
2000). A recent re-evaluation of five 
clinical studies, designed with a primary 
skeletal end point on a total of 780 women 
in their 3rd, 5th and 8th decades, showed 
significant negative associations between 
calcium intake and body weight in all age 
groups across nearly four years of 
observation (Davies et al. 2000). Estimates 
of the relationship indicated that a 1000 
mg daily calcium intake difference is 
associated with as much as 8 kg difference 
in body weight and that calcium intake 
explains approximately 3% of the variance 
in body weight. 
 
Epidemiological analysis of both the 
NHANES I (McCarron et al. 1984) and 
NHANES III databases have revealed an 
inverse association with body weight and 
dietary calcium intake (Zemel et al. 2000). 
Moreover, calcium adjusted for energy 
intake had a negative relationship with 
two-year changes in total body weight and 
body fat in young women in a prospective 
analysis of an exercise intervention study 
(Lin et al. 2000). Also a recent longitudinal 
study in preschool children showed that 
higher intake of calcium was associated 
with lower body fat (Carruth & Skinner 
2001). 
 
Recently, a new theory about regulation of 
intracellular calcium as a fundamental 
factor linking together obesity, insulin 
resistance and hypertension has been 
presented (FIGURE 2; Zemel 1998; Zemel 
2001). It was discovered that increasing 
intracellular calcium concentration 
stimulates the expression and activity of 
fatty acid synthase (FAS) and inhibits 
lipolysis in human and murine adipocytes 
via a calcium-dependent mechanism 
(Jones et al. 1996; Xue et al. 1998). 
Moreover, vitamin D and PTH were 
shown to produce sustained increases in 
adipocyte intracellular calcium and a 
corresponding inhibition of lipolysis 
(Zemel et al. 2000). This phenomenon 
may also contribute to the high body 
weight and fat mass reported in primary 
hyperparathyroidism (Grey et al. 1994). 
Increased intracellular calcium in fat and 
muscle cells may even interfere with signal 
transduction and attenuate insulin 
response (Zemel 1998). The levels of PTH 
and vitamin D are elevated during low 
intakes of calcium. An increase in dietary 
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calcium intake should, accordingly, 
suppress these calcitrophic hormones and 
thereby reduce intracellular calcium 
concentration and lipid storage in 
adipocytes; these effects together with 
reduction in body weight were indeed 
observed in calcium supplemented obese 
mice (Shi et al. 2001).  
 
In conclusion, the possible role of calcium 
in the regulation of adiposity is a fairly 
novel idea and not usually quoted in 
calcium-related reviews. It has a plausible 
physiological basis and a good deal of 
experimental as well as some recent 
clinical and population data to support it. 
However, larger intervention studies 
should be performed to define the true 
significance of this action. 
 
 
2.1.6 ADVERSE EFFECTS OF CALCIUM 
 
Dietary calcium intake up to 2000 mg/d is 
generally recognized as safe (NIH 
Consensus Panel 1994). However, no 
research data in humans are available 
about the long-term risks or benefits of 
consuming higher amounts. Clinical 
toxicity of excessive calcium intakes could 
rise from development of hypercalcemia; 
symptoms may include confusion, fatigue, 
irritability, in severe cases even cardiac 
arrhythmias and, particularly with 
associated hyperphosphatemia, soft tissue 
calcification and renal damage (Spiegel 
1996). True life-threatening toxicity is rare: 
there are about 30 case reports from the 
last two decades of the milk-alkali 
syndrome, and most of them had a 
predisposing factor, such as thiazide 
diuretic treatment or concurrent high alkali 
intake (Whiting & Wood 1997). High 
calcium intake has also been thought to 
cause kidney stones, for which 
hypercalciuria is an important risk factor 
(Whiting & Wood 1997). However, more 
recent studies suggest that increased 
dietary calcium may actually reduce the 
risk of nephrolithiasis (Heller 1999). 
Although dietary calcium increases urine 
calcium, it also binds phosphate and oxalic 
acid in the intestine, thereby reducing the 
formation of calcium oxalate and calcium 
phosphate crystals in the kidney. A normal 
rather than low calcium intake provided 
protection against recurrent stones even in 
patients with idiopathic hypercalciuria 
(Borghi et al. 2002). Moreover, with long-
term consistent increase in calcium intake, 
intestinal adaptation mechanisms reduce 
the fractional calcium absorption, which 
already is highly dependent on the dietary 
source (Weaver et al. 1999). On the other 
hand, while reducing the likelihood of 
adverse effects, this adaptation may also 
reduce the expected benefits of calcium 
supplementation. 
 
Another possible adverse effect of 
excessive calcium intake is the interaction 
with the absorption of other essential 
minerals, such as iron, magnesium, and 
zinc (Whiting & Wood 1997). The 
interaction between calcium and iron has 
been extensively studied. Calcium clearly 
inhibits iron absorption in a dose-
dependent manner and, surprisingly, even 
heme iron absorption is inhibited (Hall-
berg et al. 1991). A recent review, 
however, concluded that while this is true 
in short-term absorption studies, long-term 
consumption of calcium supplements does 
not affect overall iron status (Bendich 
2001). Calcium supplements may also 
affect the magnesium status of the body. It 
has been proposed that a dietary calcium 
to magnesium ratio greater than five may 
pose a risk for magnesium deficiency, 
partly because of reduced absorption but 
also because of increased excretion (Seelig 
1994). This emphasizes the importance of 
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adequate or increased magnesium intake 
concurrently with calcium supplemen-
tation. In practice, though, high-calcium 
diets have not been demonstrated to affect 
magnesium retention in the long-term, 
probably due to the powerful compen-
satory function of the kidneys to decrease 
magnesium excretion (Whiting & Wood 
1997). As for zinc, early animal studies 
indicated that high-calcium diets decrease 
its bioavailability, but most later studies in 
humans have not found any effect of 
calcium on either the absorption or whole-
body retention of zinc (Whiting & Wood 
1997). 
 
Particularly calcium supplements can 
produce gastrointestinal side effects like 
bloating and constipation; they can also 
diminish the effectiveness of some 
medications such as alendronate, used to 
treat osteoporosis, or the antibiotic 
tetracycline, and should therefore not be 
consumed at the same time (Miller et al. 
2001). 
 
In conclusion, little evidence exists for any 
general toxicity of calcium intakes of even 
more than 2 g/d, especially if consumed 
with food when most of the calcium is not 
even absorbed. However, patients with 
hypercalcemia, thiazide treatment, or 
propensity to hypercalciuric stone 
formation should be more careful to keep 
to the recommended range. 
 
 
 
2.2 MAGNESIUM  
 
Magnesium is the most abundant intra-
cellular divalent cation. It is an essential 
cofactor for a multitude of enzymatic 
reactions that are important for the 
generation of energy from ATP and for 
physiologic processes including neuro-
muscular function and maintenance of 
cardiovascular tone (for review, see Saris 
et al. 2000).  
 
The serum concentration of magnesium is 
tightly regulated within a narrow range of 
0.71.1 mmol/l as a result of the efficient 
absorption of dietary magnesium by the 
small intestine and conservation of 
magnesium in the kidney. The current 
RDA for magnesium is 400 mg/d; in 
Finland, the mean daily intake is about 
400 mg in men and 300 mg in women 
(National Public Health Institute 1998). 
About 30% of dietary magnesium is 
absorbed in the small intestine, but this 
fraction can be substantially increased 
when intake is reduced. Approximately 
96% of filtered magnesium is reabsorbed 
along the nephron, and only 4% is 
excreted into the urine. Hypercalcemia 
and hypercalciuria decrease tubular 
reabsorption of magnesium. Also excessive 
sodium intake and certain drugs, 
particularly thiazide diuretics, increase 
magnesium loss into the urine. There 
appears to be no specific and direct 
endocrine control of magnesium balance, 
similar to what exists for calcium, sodium 
and potassium. The calcitrophic hormones 
PTH, vitamin D and calcitonin, however, 
have similar actions for calcium and 
magnesium (Saris et al. 2000). 
 
Magnesium deficiency may play an 
important role in the pathogenesis of 
several cardiovascular diseases, including 
cardiac arrhythmias, ischemic heart 
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disease, congestive heart failure, vascular 
complications of diabetes, hypertension 
and stroke (Arsenian 1993; Liao et al. 
1998). Current dietary recommendations 
include the maintenance of adequate 
intake of magnesium, along with calcium 
and potassium, in order to lower the risk of 
cardiovascular diseases (Krauss et al. 
2000). 
 
 
2.2.1 MAGNESIUM AND LIPIDS 
 
Several studies have evaluated the effects 
of dietary magnesium on serum and tissue 
lipids. In an early study in rats, 0.2% 
magnesium supplementation had no effect 
on serum cholesterol, but it effectively 
reduced tissue calcification and vascular 
lipid accumulation (Vitale et al. 1959). In a 
six-month experiment with cholesterol-fed 
rabbits (Renaud et al. 1983), 0.4% dietary 
magnesium markedly lowered serum total 
cholesterol and reduced the accumulation 
of cholesterol as well as the severity of 
atherosclerosis in the aorta. Another study 
in rabbits (Ouchi et al. 1990) showed no 
changes in cholesterol levels but, again, 
additional magnesium dose-dependently 
decreased both the area of aortic lesions 
and the cholesterol content in the aortas. 
Altura et al. (1990) demonstrated up to 
40% lowering of cholesterol and 
triglyceride levels along with marked 
attenuation of the atherosclerotic process 
by magnesium supplementation in 
cholesterol-fed rabbits. Recently, increased 
magnesium intake was reported to reduce 
both cholesterol and triglyceride levels and 
inhibit atherogenesis in apo-E deficient 
mice receiving a low-fat diet (Ravn et al. 
2001). 
 
In humans, two similar randomized, single-
blinded, controlled studies with 430 (Singh 
et al. 1990) and 400 patients (Singh et al. 
1991) showed about 10% decreases in 
serum total and LDL cholesterol and 
triglyceride concentrations as a result of an 
increase in dietary magnesium intake from 
about 400 to 1000 mg/d. HDL cholesterol 
remained mostly unchanged, however, in 
originally hypomagnesemic subjects the 
dietary change induced an 11% increase 
in serum HDL cholesterol together with 
the decrease in the other lipids (Singh et 
al. 1990). A 500 mg/d oral magnesium 
supplementation lowered serum tri-
glycerides but had no positive effect on 
cholesterols in a study with 69 
hyperlipidemic patients on a low-fat, low-
cholesterol diet (Kisters et al. 1993). 
Recently, magnesium supplementation 
was found to reduce both serum total and 
LDL cholesterol levels and insulin-
stimulated glucose uptake in patients with 
type I diabetes (Djurhuus et al. 2001). 
 
Thus, in the light of current knowledge, 
increased intake of dietary magnesium is 
likely to have beneficial effects on serum 
lipids. Moreover, experimental data 
suggest that it may attenuate the develop-
ment of atherosclerosis even without major 
changes in the lipoprotein levels, especially 
in magnesium-deficient subjects. Magnesi-
um deficiency is not uncommon, although 
it is often clinically latent, because less 
than 1% of total body magnesium is 
present in blood, and assessment of tissue 
magnesium status is problematic (Elin 
1994). The mechanisms of the lipid-
lowering effect of magnesium are poorly 
understood. In theory, as a divalent cation 
similar to calcium, it could bind fatty acids 
and bile acids in the intestine, reduce the 
absorption of saturated fat, and increase 
the excretion of cholesterol as bile acids 
from the liver. One of the above-
mentioned studies (Renaud et al. 1983) 
reported a magnesium-induced increase in 
fecal fat excretion, but currently no data 
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are available on concomitant effects on 
bile acid excretion and serum lipids or 
atherogenesis. 
 
 
2.2.2 MAGNESIUM AND BLOOD PRESSURE 
 
Magnesium may also have a beneficial 
effect on blood pressure. No quantitative 
analyses are available, but qualitative 
overviews on epidemiological studies point 
to an inverse relationship between dietary 
magnesium intake and blood pressure 
(Whelton & Klag 1989; Mizushima et al. 
1998). The large cross-sectional Athero-
sclerosis Risk in Communities (ARIC) 
study on 15 000 middle-aged Americans 
showed a negative correlation of dietary 
and serum magnesium levels to both 
systolic and diastolic blood pressure (Ma et 
al. 1995); on the other hand, no such 
relationship was found in the NHANES III 
(Hajjar et al. 2001). Data from clinical 
studies are also inconsistent. Dietary 
magnesium supplementation has been 
shown to lower blood pressure in many 
(Dyckner & Wester 1983; Widman et al. 
1993; Kawano et al. 1998) but not in all 
(Cappuccio et al. 1985; Ferrara et al. 
1992; Sacks et al. 1998) intervention 
studies. 
 
 
2.2.3 MAGNESIUM AND OBESITY 
 
Little is known about the effects of dietary 
magnesium on obesity, and no reductions 
of body weight attributable to increased 
magnesium intake were reported in any of 
the studies referred to above. 
Theoretically, magnesium could have an 
anti-obesity effect similar to calcium, 
because it too can form soaps with fatty 
acids in the intestine and thus reduce the 
digestible energy content of the diet 
(Givens 1917; Drenick 1961). 
Furthermore, there is both experimental 
(Balon et al. 1995) and epidemiological 
evidence (Kao et al. 1999) that magne-
sium may attenuate the development of 
insulin resistance and type II diabetes, and 
insulin response has been reported to be 
improved by magnesium administration 
(Paolisso et al. 1989); this should also 
eventually affect adiposity. Interestingly, in 
a recent study obese persons were found 
more insulin-resistant and had lower 
magnesium concentrations in their serum 
and erythrocytes than nonobese controls 
(Zemva & Zemva 2000). Also the ARIC 
study reported an inverse relation between 
serum magnesium concentration and body 
mass index at baseline (Kao et al. 1999). 
 
 
2.2.4 ADVERSE EFFECTS OF MAGNESIUM 
 
The therapeutic window of magnesium is 
wide and severe toxic effects are extremely 
rare (for review, see Saris et al. 2000). 
Oral magnesium supplementation has a 
laxative effect that is even utilized in 
treatment of constipation, but large doses 
may also cause diarrhea and abdominal 
cramps. Signs of magnesium toxicity are 
vomiting, hypotension, bradycardia and 
other arrhythmias, somnolence, and 
weakness; these usually occur at plasma 
levels of four to five times higher than 
normal, and have only been observed 
during intravenous magnesium treatment. 
Magnesium toxicity is increased in patients 
with hypocalcemia, hyperkalemia and 
renal failure. Calcium gluconate is 
clinically used as an antidote for 
magnesium; therefore, with concurrent 
dietary supplementation of calcium and 
magnesium, any adverse effects 
attributable to magnesium are unlikely. 
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2.3 POTASSIUM 
 
Potassium is the principal intracellular 
cation and mainly involved in membrane 
potential and electrical excitation of nerve 
and muscle cells. The extracellular 
concentration of potassium is kept 
constant at 45 mmol/l by active ion 
transport systems, which are usually 
coupled with the regulation of sodium 
concentration and excretion as well. Until 
recently, from an evolutionary point of 
view, humans consumed a diet low in 
sodium (about 0.51 g/d) and high in 
potassium (810 g/d), but these days the 
relation has often turned the other way 
around, largely as a result of the increasing 
consumption of industrially processed 
foods (Eaton & Konner 1985; Tobian 
1997). The current Finnish recommend-
ation for potassium intake is 3.5 g/d, and 
mean daily intake about 4.2 g in men and 
3.3 g in women, whereas the intake of 
sodium is 3.7 g and 2.5 g, respectively 
(National Public Health Institute 1998).  
 
In addition to its widely accepted role in 
the prevention and treatment of 
hypertension, high intake of potassium 
may also have other beneficial effects that 
are independent of blood pressure  for 
example, reduction of the risk of stroke, 
prevention of renal vascular, glomerular 
and tubular damage, and improvement in 
glucose intolerance (for review, see He & 
MacGregor 2001). In the Scottish Heart 
Health Study, findings included an 
unexpectedly powerful protective relation 
of dietary potassium to all cause mortality 
(Tunstall-Pedoe et al. 1997). Potassium 
also decreases urinary calcium excretion 
and thereby has many effects comparable 
to increased calcium intake, such as 
reduced risk of osteoporosis and kidney 
stones. Increasing potassium intake and 
reducing sodium intake have an additive 
effect in most of these conditions (He & 
MacGregor 2001).  
 
 
2.3.1 POTASSIUM AND LIPIDS 
 
There appears to be no direct evidence of 
any effect of dietary potassium on serum 
lipid levels in humans or in animals. 
However, potassium may protect against 
atherosclerosis by modifying lipid 
properties even without significant changes 
in their concentrations. In cholesterol-fed 
rabbits, increasing dietary potassium from 
0.4% to 1.5% did not produce any 
differences in plasma cholesterol or body 
weight in six weeks, yet substantially 
reduced atherosclerotic lesions in coronary 
arteries (Ma et al. 1999). Other 
experimental studies have provided 
explanations for possible mechanisms by 
which increased intake of potassium may 
protect against cardiovascular diseases. 
Potassium has been shown to 1) inhibit 
free radical formation from vascular 
endothelial cells and macrophages 
(McCabe et al. 1994), which could also 
affect LDL oxidation and thereby the 
development of atherosclerosis; 2) inhibit 
proliferation of vascular smooth muscle 
cells (McCabe & Young 1994); and 3) 
inhibit platelet aggregation and arterial 
thrombosis (Lin & Young 1994). Recently, 
a high level of dietary potassium was 
shown to inhibit neointimal proliferation 
after balloon angioplasty in the rat carotid 
artery (Ma et al. 2000) as well as in a 
swine coronary artery (Ma et al. 2001). 
 
 
2.3.2 POTASSIUM AND BLOOD PRESSURE 
 
The important role of potassium intake in 
regulating blood pressure in both the 
general population and people with high 
blood pressure has been repeatedly shown 
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in epidemiological as well as clinical 
studies, and is today well established 
(Kotchen & McCarron 1998; He & 
MacGregor 1999).  For instance, pooled 
data from a meta-analysis of 33 trials 
(2609 patients) on the effects of potassium 
supplementation showed highly significant 
net decreases of 4.5 mmHg in systolic and 
2.5 mmHg in diastolic blood pressure with 
a median dose of 1.9 g/d (Whelton et al. 
1997). Very recently, an analysis of the 
NHANES III database on 17030 subjects 
again confirmed that higher potassium 
intake is associated lower systolic and 
diastolic blood pressure (Hajjar et al. 
2001). 
 
The blood pressure-lowering effect has 
been particularly prominent in patients 
and animals with salt-sensitive hyper-
tension (Karppanen 1991; Tobian 1997); 
thus, the action of potassium could be 
related to facilitation of natriuresis and 
decrease in volume load. However, the 
antihypertensive effect is most likely multi-
factorial; suggested mechanisms include 
reduced sympathetic nervous activity 
(Fujita & Sato 1992) and decreased 
pressor response to noradrenaline and 
angiotensin II (Campbell & Schmitz 1978). 
Experimental studies with a potassium-
enriched mineral salt have supported the 
volume load theory (Mervaala et al. 1992), 
but also indicated that potassium may 
attenuate the vascular contractile 
responses and improve both endothelium-
dependent and -independent relaxation 
(Mervaala et al. 1994). Recently, Tolvanen 
et al. (1998) showed that dietary 
potassium supplementation improved 
endothelium-dependent arterial relaxation 
in spontaneously hypertensive rats by 
mechanisms involving enhanced hyper-
polarization, increased smooth muscle 
sensitivity to nitric oxide and decreased 
production of vasoconstrictor prostanoids. 
Increased intake of calcium together with 
potassium was more effective than either 
one alone in reducing blood pressure and 
restoring arterial tone. In another recent 
study, the most effective protection against 
hypertension induced by cyclosporin toxi-
city was achieved when dietary potassium 
and magnesium supplementations were 
combined (Pere et al. 2000). 
 
 
2.3.3 POTASSIUM AND OBESITY 
 
There are no reports in the literature that 
would closely link together dietary 
potassium and obesity, and only sparse 
references to point to even a distant 
connection. However, as with magnesium, 
type II diabetes might be the common link: 
improvements in carbohydrate metabolism 
in response to potassium administration 
have been reported (Rapoport & Hurd 
1964; McFarland & Carr 1977; Karppanen 
et al. 1984). Furthermore, decreased 
skeletal muscle potassium and increased 
sodium to potassium ratios have been 
measured in obese and glucose intolerant 
men (Landin et al. 1988; Landin et al. 
1991). A recent study demonstrated that 
insulin and leptin, hormones that reduce 
food intake and body weight in lean but 
not obese Zucker rats, hyperpolarize 
hypothalamic glucose-responsive neurons 
by opening ATP-sensitive potassium 
channels, suggesting that this potassium 
channel is involved in the physiological 
regulation of energy homeostasis 
(Spanswick et al. 2000). There is no 
evidence to date about any effect of 
dietary potassium on the function of this 
channel, but knowing that potassium 
supplementation can enhance hyper-
polarization in vascular smooth muscle 
cells via its action on potassium channels 
(Tolvanen et al. 1998), this kind of a 
mechanism could be speculated. 
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2.3.4 ADVERSE EFFECTS OF POTASSIUM 
 
The renal mechanisms for potassium 
excretion adapt efficiently to increases in 
the rate of potassium influx to extracellular 
fluid, particularly from dietary sources. 
Hence acute or chronic hyperkalemia due 
to exogenous potassium intake is 
uncommon, but usually occurs as a result 
of either potassium release from cells or 
decreased renal excretion (for review, see 
Kokko 1996). However, iatrogenic hyper-
kalemia may result from excessive 
parenteral potassium replacement, in 
patients with renal insufficiency, or with 
certain drugs like potassium-sparing 
diuretics and ACE-inhibitors. Particularly 
potassium supplements may be hazardous, 
and case reports of even severe hyper-
kalemia following abundant ingestion of 
potassium chloride either as salt substitutes 
or tablets have been published (Schim van 
der Loeff HJ et al. 1988; McCaughan 
1984; Browning & Channer 1981). 
Moreover, potassium chloride is irritating 
to the gastrointestinal tract, even to the 
extent of causing perforation. 
 
Since the resting membrane potential is 
related to the ratio of the intracellular to 
extracellular potassium concentration, 
hyperkalemia partially depolarizes the cell 
membrane. Prolonged depolarization 
impairs membrane excitability and is 
manifested as weakness, which may 
progress to flaccid paralysis and 
hypoventilation if the respiratory muscles 
are involved. The most serious effect of 
hyperkalemia is cardiac toxicity. Electro-
cardiographic changes include increased 
T-wave amplitude, prolonged PR interval 
and QRS duration, and atrioventricular 
conduction delay, which may eventually 
lead to ventricular fibrillation or asystole 
(Kokko 1996). 
In general, a moderate increase in dietary 
potassium intake is not likely to produce 
any toxic effects, unless its renal excretion 
is severely compromised. The regulatory 
mechanisms of the human body have 
evolved to save sodium and actively 
excrete potassium; the current high dietary 
sodium intake, especially in ratio to 
potassium, goes against this adaptation 
and is much more likely to cause problems 
(Tobian 1997). 
 
 
2.4 PLANT STEROLS 
 
Sterols are essential components of all 
cell membranes both in animals and 
plants. The sterol ring is common to all 
sterols; the differences are in the side 
chain (FIGURE 3). Cholesterol is the 
exclusive sterol in mammalian cells, 
whereas   numerous   other   sterols   are 
 
 
 
 
Fig 3.
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produced by plants (for review, see Jones 
et al. 1997). Over 40 plant sterols (or 
phytosterols) have been identified, but β-
sitosterol, campesterol and stigmasterol 
are the most abundant in nature. 
Although structurally similar to chole-
sterol, plant sterols are not synthesized by 
the human body. Stanols are saturated 
derivatives of sterols, and less common in 
nature than sterols. 
 
The dietary intake of plant sterols is an 
estimated 100200 mg/d and subject to 
great variation, while the intake of 
cholesterol is about 500 mg/d; vegetable 
oils and cereal products are the most 
important sources of plant sterols in the 
average Western diet (Jones et al. 1997). 
Plant sterols and stanols especially are 
very poorly absorbed from the intestine. 
 
The specific sterols and stanols that are 
currently incorporated into foods are 
extracted from soybean oil or tall oil, and 
usually esterified to fatty acids to increase 
lipid solubility (Lichtenstein & Deckelbaum 
2001). In the following, the term plant 
sterol is used for all plant-derived sterols 
and stanols, and natural plant sterol 
refers specifically to the non-esterified 
forms. 
 
2.4.1 PLANT STEROLS AND SERUM 
LIPIDS 
 
The cholesterol-lowering properties of 
plant sterols have been known since the 
1950s (Pollak 1952), but almost forgotten 
until the emergence of the functional food 
boom of the last decade, which created 
new financial and scientific interest in this 
area. Nowadays, the serum cholesterol-
lowering effect of plant sterols in patients 
with mild hypercholesterolemia is well 
established (Law 2000), and food 
products containing these compounds 
have been widely accepted as part of a 
healthy antiatherogenic diet (Lichtenstein 
& Deckelbaum 2001). Plant sterols and 
stanols have also proven effective during 
low-fat and low-cholesterol diets (Halli-
kainen & Uusitupa 1999; Hallikainen et al. 
2000), and even in combination with lipid 
lowering drugs (Blair et al. 2000).  
 
Inhibition of cholesterol absorption 
Plant sterols lower serum cholesterol levels 
mainly by reducing the absorption of 
cholesterol from the intestine; they do this 
by competing for the limited space and 
reducing the solubility of cholesterol in 
mixed micelles formed by the action of 
bile salts, cholesterol and fatty acids (for 
review, see Lu et al. 2001). These micelles 
deliver the mixtures of lipids for absorption 
into the surface of the enterocyte brush 
border. Cholesterol appears to be 
specifically removed from the micelles as 
part of the absorption process, while non-
cholesterol sterols such as sitosterol, even 
if presented at the brush border 
membrane, are largely excluded from 
entry and esterification (Lu et al. 2001). A 
small part of plant sterols, however, is 
absorbed and this fraction appears to be 
proportionate to cholesterol absorption 
efficiency; therefore, the serum concentra-
tions of plant sterols can be used as 
markers of intestinal cholesterol absorption 
(Tilvis & Miettinen 1986; Miettinen et al. 
1990). The exact mechanism of the 
absorption of cholesterol is still unknown; 
however, it is not simple diffusion as 
previously thought, but an energy-
dependent, protein-mediated process (Lu 
et al. 2001). Probably it is controlled by 
nuclear hormone receptors, which regulate 
the expression of transporter proteins such 
as the scavenger receptor class B type 1 
(SR-B1) (Hauser et al. 1998) and possibly 
also by the ATP-binding cassette, ABCA1 
(Chen 2001) on the enterocyte 
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membrane. After absorption, the free 
sterols and fatty acids are esterified in the 
enterocytes by the action of acyl-
CoA:cholesterol acyl-transferace (ACAT), 
packaged with triglycerides, phospholipids 
and apo-B48 into chylomicrons, and 
finally secreted to the lymphatic channels 
to be transported into the peripheral 
circulation (Lu et al. 2001). Only a small 
part, generally less than 510%, of the 
ingested plant sterols are present at these 
later stages of absorption, but it is possible 
that they affect some of the enzymes at 
this level as well (Ling & Jones 1995). 
 
Effects on cholesterol metabolism 
Endogenous synthesis of cholesterol is 
stimulated as a compensatory response to 
cholesterol malabsorption and depletion of 
the hepatic cholesterol pool by plant 
sterols (Vanhanen et al. 1993; Jones et al. 
2000). However, the increased synthesis is 
not able to fully compensate for the 
intestinal loss, and so serum LDL 
cholesterol concentrations decrease: at the 
recommended dose of 2 g/d the decrease 
in LDL cholesterol is usually about 10% in 
mildly hypercholesterolemic subjects (Law 
2000; Lichtenstein & Deckelbaum 2001). 
Lipoprotein kinetic studies have associated 
the decreased LDL cholesterol levels with 
a decreased production rate of LDL apo-
B; the general lack of effect of plant sterols 
on HDL cholesterol levels was reflected in 
essentially no change in the kinetic 
parameters of HDL apo-A1 (Gylling & 
Miettinen 1994).  
 
FIGURE 4 shows a simplified scheme of the 
cholesterol synthesis pathway, highlighting 
the immediate precursor sterols, which can 
be measured by gas liquid chromato-
graphy from serum sterol extract. ∆8-
cholestenol, desmosterol, lathosterol and, 
less consistently, squalene, have been 
found to reflect cholesterol synthesis 
(Miettinen 1970; Miettinen et al. 1990), 
and their ratios to serum cholesterol are 
generally used to evaluate the effects of 
plant sterols and other dietary and drug 
interventions on the endogenous synthesis 
of cholesterol (Miettinen et al. 1995; 
Miettinen et al. 1998; Gylling et al. 1999; 
Relas et al. 2000). 
 
 
 
Fig 4. Synthesis of cholesterol (adapted from 
Relas 2000) 
 
 
2.4.2 PLANT STEROLS AND BLOOD 
PRESSURE 
 
Plant sterols are not commonly thought to 
affect blood pressure in any way, and no 
data about studies examining this question 
in either animals or humans appears to be 
available. However, through their 
cholesterol-lowering action, plant sterols 
might be speculated to have indirect long-
term effects on blood pressure. For 
example, there is considerable experi-
mental and clinical evidence that 
hyperlipidemia can induce glomerular 
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injury, and that treatment of hyperlipid-
emia can reduce this damage (Kasiske et 
al. 1988; Kasiske et al. 1990; Greco & 
Breyer 1997); renal dysfunction, in turn, 
will almost inevitably produce hyper-
tension (Hall et al. 1999; Adamczak et al. 
2002) . Furthermore, hyperlipidemia is 
known to induce endothelial dysfunction 
(Ross 1999; Kinlay et al. 2001), and even 
short-term intensive cholesterol reduction 
lowers blood pressure and large artery 
stiffness (Ferrier et al. 2002). The blood 
pressure lowering effect of statins, though, 
may also be related to their direct 
interaction with endothelial function or 
angiotensin II receptors (Borghi et al. 
2001), and there is no direct evidence that 
plants sterols would produce a similar 
effect. In an experimental study, β-
sitosterol did not have any relaxing effect 
on mesenteric artery in vitro (Nevala et al. 
1998). 
 
2.4.3 PLANT STEROLS AND OBESITY 
 
Although obesity and serum lipids are 
closely related, very little is known about 
the effects of plant sterols or any other 
lipid-lowering therapies on body fat. In 
experimental studies, decrease in body 
weight is usually considered a sign of 
toxicity, and no such effect has been 
observed with up to 8.1% (w/w) dietary 
levels of plant sterols (Hepburn et al. 
1999). On the other hand, plant sterols are 
usually supplemented with fat, which may 
even increase energy intake and fat 
deposition. In randomized clinical studies 
that have reported body weights, no 
significant effect attributable to plant 
sterols or stanols have been found 
(Miettinen et al. 1995; Hallikainen & 
Uusitupa 1999; Hallikainen et al. 2000; 
Davidson et al. 2001; Mensink et al. 
2002). Effects of plant sterols in obese 
subjects in particular have not been 
studied. Recently, however, it was shown 
that sitosterol inhibits cell growth and 
triglyceride accumulation in 3T3-L1 cells, 
which is an in vitro model for obesity 
research (Awad et al. 2000). This suggests 
that at least the absorbed and circulating 
part of plant sterols could play a role in the 
control of adiposity. 
 
2.4.4 ADVERSE EFFECTS OF PLANT 
STEROLS 
 
Based on extensive safety evaluation 
studies, both plant sterols and stanols are 
generally recognized as safe (for review, 
see Plat et al. 2000). However, while plant 
sterols inhibit the absorption of cholesterol, 
they may also interfere with the absorption 
of other lipid soluble components, such as 
vitamins and antioxidants. Most studies 
have found that plant sterols lower plasma 
levels of α-carotene, β-carotene and 
lycopene, but not the vitamins A, D or K 
(Hallikainen et al. 1999; Plat et al. 2000). 
After lipid standardization, even the 
carotene-lowering effect has often 
disappeared; the same applies for plasma 
tocopherols as well (Hallikainen et al. 
2000; Plat et al. 2000). The clinical 
importance of these changes is not known; 
the observed reductions have not been 
dose-dependent for either the carotenoids 
or the tocopherols, and their plasma levels 
have always been within the normal 
ranges.  
Earlier findings in fish have suggested that 
plant sterols may have estrogenic activity 
and effects on the reproductive system 
(MacLatchy & Van Der Kraak 1995; Mel-
lanen et al. 1996). In recent studies, how-
ever, no evidence of any such effects of 
even very large doses have been found in 
other species in experimental (Baker et al. 
1999; Waalkens-Beerendsen et al. 1999) 
or clinical conditions (Ayesh et al. 1999). 
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3 AIMS OF THE STUDY 
 
 
 
 
The present series of experiments was designed to examine the possible benefits of the use 
of a dietary combination of mineral nutrients and natural plant sterols to serum lipids, 
blood pressure and body weight, to find an optimal combination of these components, 
and to provide some insight into the mechanisms of the effects observed in an 
experimental model of obesity and the metabolic syndrome, the obese Zucker rat. 
 
More specifically, the aims of the experiments were: 
 
1. To compare the effects of a combination of plant sterols and the mineral nutrients 
calcium, magnesium and potassium, with the effects of the plant sterols alone or 
the minerals alone on serum cholesterol and body weight during a high-fat and 
high-cholesterol diet. 
 
2. To compare the effects of a combination of plant sterols and the divalent cations 
calcium and magnesium with the effects of a combination of plant sterols and the 
monovalent cations sodium and potassium on serum cholesterol and body weight 
during a high-fat and high-cholesterol diet. 
 
3. To evaluate the effects of different dietary calcium levels, and interaction between 
calcium and plant sterols, on serum lipid profile and absorption and synthesis of 
cholesterol during both low- and high-fat diets. 
 
4. To examine the long-term effects of the combination of plant sterols and the 
mineral nutrients calcium, magnesium and potassium on serum lipids, blood 
pressure, endothelium-mediated vasodilation, and survival in the obese Zucker rat. 
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4 MATERIALS AND METHODS 
 
 
 
 
4.1 EXPERIMENTAL ANIMALS 
 
Female obese Zucker rats were purchased 
from Harlan (Oxon, UK). The rats were 
housed in groups of three or four in plastic 
cages in an animal laboratory at a room 
temperature of 2224°C with a 12-hour 
light/dark cycle. After an initial adaptation 
period of one or two weeks, the 813 
week-old rats were matched for body 
weight and serum cholesterol and divided 
into experimental groups to receive 
different diets. They had free access to the 
food and tap water at all times. 
 
 
4.2 DIETS 
 
The experimental diets were based on a 
commercial low-mineral rat chow 
(Altromin, Lage, Germany) into which 
cholesterol, unsalted butter, sodium, 
calcium, magnesium and/or potassium 
salts (or a commercially available mineral 
salt), and a pine oil-derived plant sterol 
mixture (UPM-Kymmene, Lappeenranta, 
Finland) were added. The chemical 
composition of the powder was as follows: 
β-sitosterol 79.2%, sitostanol 11.4%, 
campesterol 7.5%, campestanol 1.2%, 
cycloartenolol 0.5%, and δ-7-avenasterol 
0.2%. The different components were 
mixed with powdered rat chow, and 
moistened with water using an industrial 
dough mixer. The chow preparations were 
then packed in one-day portions and 
stored at 20 °C. 
 
The exact compositions of the diets in 
each study are given in the original 
publications IIV. A summary of the 
experimental design of the studies is 
presented in TABLE 4. 
 
 
4.3 MEASUREMENT OF BLOOD 
PRESSURE AND HEART RATE 
 
 
4.3.1 TAIL-CUFF METHOD 
 
Systolic blood pressure and heart rate of 
the pretrained rats were measured using a 
tail-cuff analyzer (Apollo-2AB Blood 
Pressure Analyzer, Model 179-2AB, IITC 
Life Science, Woodland Hills, CA, U.S.A.). 
The digital values for systolic blood 
pressure and heart rate were evaluated 
automatically from the analog data by a 
microprocessor. Before the measurements 
the rats were warmed for 1020 minutes 
at 30°C to make the pulsations of the tail 
artery detectable. Values for systolic blood 
pressure and heart rate were obtained by 
averaging readings from three to five 
measurements.  
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4.3.2 RADIOTELEMETRY 
 
The Dataquest IV telemetry system (Data 
Sciences International. St. Paul, MN, USA) 
was used for measurements of systolic, 
diastolic and mean arterial pressure, heart 
rate and locomotor activity, as described 
previously (Brockway et al. 1991). Twelve-
week-old rats were anesthetized with 
midazolam (5 mg/kg i.p.), fentanyl (0.3 
mg/kg i.p.) and fluanisone (10 mg/kg i.p.), 
and the flexible catheter of the transmitter 
was surgically secured in the abdominal 
aorta just below the renal arteries, pointing 
against the blood flow. The transmitter was 
sutured to the abdominal wall. The rats 
were given buprenorfin (0.1 mg/kg s.c.) for 
the firs two postoperative days. They were 
housed in individual cages after the 
operation and were allowed to stabilize for 
two weeks. The rats were unrestrained and 
free to move within their cages at all times. 
The data were sampled every five minutes 
for ten seconds for each animal. The 
values for systolic, mean and diastolic 
blood pressure, heart rate and activity 
were calculated using the Dataquest 
software. Mean values were calculated for 
intervals of 60 minutes for observation of 
diurnal patterns and for intervals of 12 
hours to obtain day- and nighttime curves 
for the whole four-week period. 
 
 
4.4 METABOLIC STUDIES 
 
During the last week of each study, the 
rats were housed individually in metabolic 
cages. Food intake was measured by 
weighing the food containers before and 
after the 24-hour period. Urine was also 
collected over 24 hours, its volume was 
measured, and samples were stored at      
30°C until analyzed.  
 
4.5 BLOOD SAMPLES AND TISSUE 
PREPARATION  
 
Before and during the course of the 
experiments, blood samples (~0.1 ml) 
from a superficial vein of the foot were 
taken into capillary tubes for serum 
cholesterol measurements. At the end of 
the experiments, the rats anesthetized with 
a gas mixture containing 70% CO2 and 
30% O2 (AGA, Riihimäki, Finland) and 
killed by decapitation. Blood was collected 
into chilled tubes on ice. After 
centrifugation, the serum samples were 
stored at 80°C. The heart was excised 
and washed with ice-cold saline, the great 
vessels, atria and the free wall of the left 
ventricle were dissected, and the left 
ventricular mass was measured. Kidneys, 
liver, spleen, thymus, uterus, ovaries, 
adrenal glands, and forebrain were 
dissected, washed with saline, blotted dry 
and weighed. The ratios of left ventricle, 
kidney and liver weights to skeletal body 
weight were used as indices to estimate 
hypertrophy of these organs. The left tibia 
was excised, carefully cleaned of adherent 
tissue, and measured using a micrometer, 
and the length of the tibia was used to 
estimate the lean or skeletal body weight 
of the obese rats, as suggested by Zucker 
(1965). 
 
4.6 ARTERIAL RESPONSES 
 
Immediately after decapitation, 3-mm-long 
standard sections of the superior 
mesenteric artery, 3 mm distal from the 
artery-aorta junction, were cut. The rings 
were placed between stainless steel hooks 
and mounted in an organ bath chamber in 
Krebs-Ringer buffer (pH 7.4), and aerated with 
95% O2 and 5% CO2. The rings were
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Table 4. Summary of the experimental design of the studies 
 
Study 
(substudy) 
Diet components (w/w) 
Treatment period 
Measurements 
I   (1) 
 
 
 
 
I   (2) 
Low-fat control  
Atherogenic (18% butter, 1% chol, 2.7% Na) 
    + 1% plant sterols 
    + minerals (1.9% K, 0.16% Mg, 2.9% Ca)  
    + plant sterols and the minerals 
7 weeks 
High-fat (18% butter, 1% cholesterol) 
    + 1% plant sterols 
        + 1.8% Na and 1.6% K 
        + 1.8% Ca and 1.6% Mg 
4 weeks 
 
Serum cholesterol 
Serum and liver sterols  
Serum glucose and insulin 
Body weight 
Heart, kidney, liver weights 
Food intake 
Urine minerals 
 
II  (1) 
 
 
II  (2) 
 
 
 
II  (3) 
 
 
 
II  (4) 
Low-fat + 0, 0.5, 1, 2, and 4% cholesterol 
2 weeks 
 
Low-fat + 1% cholesterol  
    + 0, 0.5, 1, 2, and 4% plant sterols 
4 weeks 
 
Low-fat, 1% cholesterol  
    + 0.2, 0.8 and 2.1% calcium 
8 weeks 
 
Low-fat, 1% cholesterol  
    + 0.2 and 2.1% calcium, 1% plant sterols 
8 weeks 
 
Serum cholesterol 
 
Organ weights 
Blood count  
 
 
 
 
Serum total, LDL and HDL 
cholesterols, triglycerides, non-
cholesterol sterols 
 
 
III High-fat (18% butter, 1% cholesterol) 
    + 0.2, 0.8 and 2.1% Ca 
    + 0.2, 0.8 and 2.1% Ca, 1% plant sterols 
8 weeks 
 
Serum total, LDL and HDL 
cholesterol, triglycerides, non-
cholesterol sterols 
Food intake, body weight 
IV Low-fat control 
Atherogenic (18% butter, 1% chol, 2.4% Na) 
    + plant sterols and minerals 
       (1.2% Na, 1.2% K, 1.7% Ca, 0.1% Mg) 
 
4 weeks  2 years 
Serum cholesterols 
Blood pressure 
Arterial responses in vitro 
Food intake, body weight, 
urine minerals and protein 
Long-term survival 
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equilibrated for 20 minutes at +37°C with 
a resting tension of 1.0 g. The force of 
contraction was measured with an 
isometric force-displacement transducer 
and registered on a polygraph (FTO3C 
transducer, Model 7C8 Polygraph, Grass 
Instrument Co., Quincy, MA, U.S.A.). The 
contractile concentration-curves to 
noradrenaline and potassium chloride, 
and the relaxation concentration-curves 
after 1 µM noradrenaline-induced pre-
contraction to acetylcholine (to test 
endothelium-dependent relaxation) and 
sodium nitroprusside (for endothelium-
independent relaxation) were determined 
as described previously (Mervaala et al. 
1994).  
 
4.7 TISSUE MORPHOLOGY 
 
In the long-term survival experiment (IV), 
rats that were either paralyzed or otherwise 
clearly ill, i.e. stopped moving and eating, 
were killed by decapitation and coded as 
dead on the same day, according to the 
ethical guidelines of the Animal 
Experimentation Committee. From these 
few rats, heart and kidney tissue samples 
were taken. After excision, the samples 
were fixed in phosphate buffered 
formaline and then prepared following 
standard laboratory procedures, de-
hydrated, embedded in paraffin and cut 
into 3 µm sections, stained with Massons 
trichrome, and examined and photo-
graphed under light microscopy. 
 
4.8 BIOCHEMICAL ANALYSES 
4.8.1 SERUM LIPIDS, GLUCOSE AND 
INSULIN CONCENTRATIONS 
 
Serum cholesterol and glucose were 
measured during the experiments using an 
automatic analyzer (Reflotron, Boeh-
ringer Mannheim, Germany). Serum lipids 
from the samples taken at the end of the 
experiments were analyzed by an 
accredited laboratory, United Laboratories 
Ltd., Helsinki, Finland (Hitachi 912 
Automatic Analyzer, Hitachi Ltd. Tokyo, 
Japan). Serum total cholesterol was 
determined with an enzymatic method 
(Boehringer Mannheim CHOD-PAP-
method), serum HDL cholesterol with an 
enzymatic direct method (Boehringer 
Mannheim HDL-Chol Plus), serum LDL 
cholesterol with an enzymatic direct 
method (Boehringer Mannheim LDL-Chol 
Plus), and serum triglycerides with an 
enzymatic method (Boehringer Mannheim 
CHOD-PAP-method). Serum insulin was 
measured using a commercial radio-
immunoassay (Incstar Corp., Stillwater, 
MN, USA).  
 
 
4.8.2 SERUM CHOLESTEROL PRE-
CURSORS AND PLANT STEROLS 
 
The concentrations of serum non-
cholesterol sterols were analyzed by gas 
chromatography mass spectrometry using 
a Hewlett-Packard (HP) 5890 gas 
chromatograph equipped with an NB-54 
fused-silica capillary column (15 m×0.20 
mm I.D.; Nordion, Helsinki, Finland) and 
interfaced with an HP 5970A mass 
spectrometry detector operating in electron 
impact mode (70 eV). The column oven 
was programmed from 230 °C to 285 °C 
at 10 °C/min and injector and detector 
were at 285 °C. The lipids from serum 
samples (200 µl) were extracted with 
chloroform/methanol (2:1) and trans-
esterified with sodium methoxide. The 
released free sterols were trimethylsilylated 
as described previously (Gylling et al. 
1999) and quantified by single ion 
monitoring technique using m/z 129 
(cholesterol, campesterol and β-sitosterol), 
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m/z 215 (β-sitostanol), m/z 343 
(desmosterol), m/z 255 (lathosterol) and 
m/z 217 (5-α-cholestane, internal 
standard) as selected ions. 
 
4.8.3 URINE ANALYSES 
 
The concentrations of the mineral 
elements and albumin and creatinine in 
urine were analyzed by the United 
Laboratories (for Na, K and Ca, 
BM/Hitachi 912 ion selective electrode, 
Boehringer-Mannheim, Germany; for Mg, 
Hitachi 180-80 Polarized Zeeman Atomic 
absorption spectrophotometer). Urinary 
excretion of the end products of nitric 
oxide metabolism, nitrate and nitrite, were 
measured using a colorimetric assay kit 
(Cayman Chemical Company, Ann Arbor, 
MI, USA). Total protein concentration in 
urine was determined by the method of 
Lowry et al. (1951).  
 
 
4.9 COMPOUNDS 
 
The following compounds were used: 
cholesterol, calcium carbonate, calcium 
chloride, potassium chloride, magnesium 
oxide, acetylcholine chloride, and nor-
adrenaline bitartrate (Sigma Chemical Co., 
St. Louis, MO, USA); sodium chloride, 
calcium chloride, and calcium carbonate 
(University Pharmacy, Helsinki, Finland); 
sodium nitroprusside (Hoffman La Roche, 
Basel, Switzerland), mineral salt 
(Pansalt®, Oriola, Espoo, Finland), plant 
sterol mixture (UPM-Kymmene, Lappeen-
ranta, Finland), midazolam (Dormicum, 
Hoffman La Roche, Basel, Switzerland), 
fentanyl-fluanisone (Hypnorm, Janssen 
Pharmaceutica, Beerse, Belgium) and 
buprenorfin (Temgesic, Reckitt & 
Colman, Hull, UK). All compounds that 
were given to the animals subcutaneously 
or intraperitoneally were dissolved in 0.9% 
NaCl solution. The stock solutions of the 
compounds used in in vitro studies were 
dissolved in distilled water. All solutions 
were freshly prepared before use and 
protected from light. 
 
 
4.10 STATISTICAL ANALYSES 
 
Statistical analysis was carried out by one-
way analysis of variance (ANOVA) 
supported by either Tukeys test or Fishers 
Least Significant Difference test. Data for 
multiple observations over time were 
analyzed by two-way ANOVA with 
repeated measures for overall treatment 
effect, and Tukeys test was used for 
multiple pair wise comparisons of 
treatment groups at different times. Data 
for dose-response relationships were 
analyzed by calculating Pearson 
correlation coefficients, followed by a two-
tailed significance test. Differences 
between means that had p < 0.05 were 
considered significant. The data were 
analyzed with SYSTAT Statistical Software 
(SYSTAT Inc., Evanston, IL, U.S.A.). The 
results are expressed as means ± S.E.M. 
 
 
4.11 ETHICS 
 
The procedures and protocols of the 
studies were in accord to the ethical 
guidelines of the Institute of Biomedicine, 
University of Helsinki, and approved by 
the Animal Experimentation Committee of 
University of Helsinki, or by the Provincial 
State Office of Southern Finland. 
 
 
 
   41   
 
5 RESULTS 
 
 
 
 
5.1 SERUM LIPIDS 
 
 
5.1.1 EFFECTS OF CALCIUM 
 
In the obese Zucker rats receiving a low-fat 
diet with 1% cholesterol (II), increases in 
dietary calcium intake from 0.2 to 0.8, and 
further to 2.1% (w/w) dose-dependently 
lowered serum total cholesterol, LDL 
cholesterol, and triglyceride concentra-
tions, and raised HDL cholesterol con-
centration, HDL cholesterol to total chole-
sterol ratio, and HDL to LDL cholesterol 
ratio. Calcium also dose-dependently 
increased the serum cholesterol precursors 
(desmosterol and lathosterol) to chole-
sterol ratios as well as the plant sterols 
(campesterol, campestanol, sitosterol, and 
sitostanol) to cholesterol ratios. 
 
In the obese Zucker rats receiving a high-
fat diet with 1% cholesterol (III), increases 
in dietary calcium intake dose-dependently 
decreased serum total cholesterol and LDL 
cholesterol concentrations. Serum HDL 
cholesterol also tended to decrease, but 
HDL to LDL cholesterol ratio was in-
creased. There was no significant correla-
tion between dietary calcium and serum 
triglyceride levels. Increases in calcium 
intake dose-dependently increased serum 
desmosterol to cholesterol and lathosterol 
to cholesterol ratios, but did not 
significantly affect serum campesterol to 
cholesterol or sitosterol to cholesterol 
ratios. 
 
5.1.2 EFFECTS OF PLANT STEROLS  
 
Dietary plant sterol supplementation dose-
dependently decreased serum cholesterol 
in the obese Zucker rats receiving a low-fat 
diet with 1% cholesterol (II). A plant sterol 
content of 1% was required for a 
statistically significant effect, and 4% 
completely prevented the diet-induced 
increase in serum cholesterol. The low-
calcium diet with 1% of plant sterols 
produced approximately 30% decrease in 
serum total cholesterol, 60% decrease in 
LDL cholesterol and 70% increase in HDL 
cholesterol, but no significant change in 
serum triglycerides. Plant sterols increased 
serum desmosterol to cholesterol and 
lathosterol to cholesterol ratios as well as 
serum plant sterols to cholesterol ratios. 
 
As compared with a diet containing 18% 
of butter and 1% of cholesterol, the 1% 
plant sterol supplementation lowered 
serum total cholesterol by approximately 
30% (I) or 40% (III); LDL cholesterol was 
lowered by about 80% and HDL 
cholesterol by 60%; triglycerides were 
increased by about 60% and HDL to LDL 
cholesterol ratio increased by 170%. Plant 
sterols supplementation tended to increase 
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serum desmosterol to cholesterol and 
lathosterol to cholesterol ratios, and serum 
plant sterols to cholesterol ratios were 
three to four fold increased in all plant 
sterols supplemented groups. 
 
5.1.3 EFFECTS OF COMBINATIONS OF 
MINERALS AND PLANT STEROLS 
 
As compared with a low-fat, low-calcium 
diet with 1% cholesterol (II), the 
combination of 2.1% dietary calcium and 
1% plant sterols produced about 20% 
decrease in serum total cholesterol, 60% 
decrease in LDL cholesterol, 180% 
increase in HDL cholesterol and 850% 
increase in HDL to LDL cholesterol ratio. 
Serum desmosterol to cholesterol ratio and 
the plant sterols to cholesterol ratios were 
significantly increased by the plant sterols 
and calcium supplementation. 
 
As compared with a high-fat, low calcium 
diet with 1% cholesterol (III), the 
combination of 2.1% dietary calcium and 
1% plant sterols produced about 70% 
decrease in serum total cholesterol, 80% 
decrease in LDL cholesterol, 60% 
decrease in HDL cholesterol and 70% 
increase in HDL to LDL cholesterol ratio. 
Both serum desmosterol to cholesterol and 
lathosterol to cholesterol ratios, and the 
plant sterols to cholesterol ratios were 
significantly increased by the plant sterols 
and calcium supplementation. 
 
During a diet containing 18% of butter 
and 1% of cholesterol (I), a supplementary 
combination of 5.5% of sodium and 
potassium salts and 1% of plant sterols 
produced about 2030% lower serum total 
cholesterol level, the same as that 
produced by plant sterols alone. In 
contrast, on a combination diet of 5.5% of 
calcium and magnesium salts with 1% 
plant sterols serum total cholesterol was 
5070% lower, i.e. the diet-induced rise of 
the cholesterol levels was completely 
prevented.  
 
In the obese Zucker rats fed an athero-
genic diet containing 18% of butter, 1% 
cholesterol and 6% of common salt (w/w), 
dietary combination of plant sterols with 
calcium, magnesium and potassium salts, 
which partly replaced the common salt 
(IV), also nearly completely prevented the 
rise in serum total cholesterol. The ten-fold 
rise in LDL cholesterol was partially 
prevented, along with an insignificant 
decrease in HDL cholesterol and rise in 
triglyceride levels; HDL to LDL cholesterol 
ratio was, however, markedly increased. In 
the long-term experiment, the total chole-
sterol levels tended to rise with advancing 
age in both groups, but the values in the 
plant sterols and mineral nutrients supple-
mented group were still after nine months 
less than half of those in the atherogenic 
diet group (p < 0.001, n = 1015 per 
group) (FIGURE 5, unpublished data). 
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5.2 BLOOD PRESSURE AND 
ARTERIAL TONE (IV) 
 
The blood pressure of the rats on the 
atherogenic diet with 18% of butter, 1% of 
cholesterol and 6% of common salt (w/w), 
increased steadily during the four-week 
experiment. The effect was most pro-
nounced in nighttime systolic pressure, but 
even daytime and mean arterial pressures 
were significantly elevated. The 1% plant 
sterols and 3% mineral nutrients supple-
mented, sodium-reduced diet completely 
prevented this hypertensive effect of the 
atherogenic diet. The pressure readings of 
this group remained on the same low level 
as those of the low-fat, low-salt diet fed 
control group, with no significant rise over 
time. 
There was considerable diurnal variation 
in the systolic and mean arterial pressures, 
heart rate and activity. All of these 
parameters showed higher readings at 
nighttime, when the rats were active and 
ate most of their food. There were no 
significant changes in the heart rate or 
activity levels over time during the four-
week experimental period. However, heart 
rate was consistently lower at all times in 
the plant sterols and minerals 
supplemented diet group as compared 
with the other groups. 
 
The endothelium-dependent relaxation 
responses to acetylcholine were 
significantly improved in the plant sterols 
and minerals supplemented diet group as 
compared with the atherogenic and 
control diet groups. The endothelium-
independent relaxations to sodium nitro-
prusside were not significantly affected by 
the diet changes. There were no significant 
differences in the contractile responses to 
noradrenaline or potassium chloride 
between the groups. 
In the long-term study, blood pressure was 
measured by the tail-cuff method until 
about nine months when many of the rats 
on the atherogenic diet had already died. 
There was a continuous rise of systolic 
blood pressure up to 180 mmHg in the 
atherogenic diet group, while the plant 
sterols and mineral nutrients supplemented 
group remained at the normal 110120 
mmHg level (p < 0.001, n = 1015 per 
group) (FIGURE 6, unpublished data). 
 
 
 
 
5.3 BODY WEIGHT, GLUCOSE 
AND INSULIN 
 
The 2.1% calcium supplemented diets in 
study III resulted in 1020% lower end 
weights as compared with the diets of 
lower calcium contents, in spite of equal or 
higher food intake. Plant sterols alone or 
in combination with sodium and 
potassium had no significant effect on 
body weight gain (III) or food intake. 
Combination of plant sterols with calcium 
(III), or calcium and magnesium (I), or 
calcium, magnesium and potassium salts 
(IV) markedly reduced the development of 
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obesity in Zucker rats during high-fat diets. 
Food and energy intakes in the calcium-
supplemented groups were the same as or 
higher than those for the other groups in 
all these studies. 
 
In the long-term study, body weight in the 
plant sterols and mineral nutrients supple-
mented group increased steadily, however, 
remaining slightly but significantly lower 
than in the atherogenic diet group until 
about five or six months, after which the 
rats on the atherogenic diet started to lose 
weight and die (FIGURE 7, unpublished 
data). 
 
 
 
Serum glucose levels of the obese Zucker 
rats were constantly about 78 mmol/l and 
did not change significantly during any of 
the dietary treatments. However, in study 
I, where also insulin levels were measured, 
the serum insulin to glucose ratio after 
seven-week treatment (µg/mmol, un-
published data) was 5.6 ± 0.7 in the low-
fat control group, 3.3 ± 0.4 in the 
atherogenic diet group, 3.8 ± 0.4 in the 
plant sterols supplemented group, 2.9 ± 
0.4 in the mineral nutrients supplemented 
group, and 1.9 ± 0.2* in the plant sterols 
and minerals supplemented group (*p < 
0.05 vs. other groups). In the second part 
of study I the serum insulin to glucose ratio 
after four-week treatment (µg/mmol, un-
published data) was 10.5 ± 1.8 in the 
high-fat control group, 9.2 ± 1.6 with 
plant sterols supplementation alone, 5.3 ± 
0.5* with plant sterols, sodium and 
potassium, and 4.3 ± 0.7* with plant 
sterols, calcium and magnesium (*p < 
0.05 vs. control group and plant sterols 
alone). 
 
5.4 SURVIVAL AND TISSUE 
MORPHOLOGY (IV) 
 
The plant sterols and mineral nutrients 
supplemented diet extended the average 
life span of the rats by 60% as compared 
with the atherogenic diet (p < 0.001, n = 
15 per group at start) (FIGURE 8, IV). Most 
of the deaths in both diet groups were 
sudden, and no samples could be 
obtained from dead animals, but in those 
few rats on the atherogenic diet that had 
to be killed, atherosclerotic lesions, 
thromboses in coronary arteries and 
myocardial infarctions were observed. In 
the kidneys, intimal thickening and 
occlusion of arteries were seen, and most 
glomeruli were destroyed. 
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6 DISCUSSION 
 
 
 
 
Dietary modifications to lower the risk of 
cardiovascular diseases are increasingly 
recommended for the general population, 
and particularly for individuals with high 
serum cholesterol, hypertension or obesity. 
Products containing plant sterols and 
stanols are already marketed for lowering 
of serum cholesterol. Potassium and 
magnesium enriched mineral salts are also 
available, and replacement of common 
salt by such mineral salts in the diet has 
been shown to lower blood pressure. 
Calcium, besides being antihypertensive, 
may also have beneficial effects on serum 
lipids. Concurrent implementation of these 
different dietary approaches may enhance 
their effects and even produce additional 
benefits (Karppanen et al. 2000), but has 
not been studied previously. Therefore, 
the present study investigated the effects of 
a combination of dietary plant sterols and 
mineral nutrients on serum lipids, blood 
pressure and obesity using Zucker rat as 
the experimental model. 
 
 
6.1 METHODOLOGICAL ASPECTS 
 
The fa/fa mutation of the genetically obese 
Zucker rat was first described by Zucker & 
Zucker (1961) and has thereafter been 
extensively characterized to exhibit 
hyperlipidemia, insulin resistance and 
renal injury as recessive traits (Zucker 
1965; Kasiske et al. 1992). The mutation 
has recently been localized in the 
extracellular domain of the leptin receptor 
(Chua et al. 1996; Phillips et al. 1996). 
Lack of leptin control of satiety leads to 
hyperphagia, which produces hyper-
insulinemia, which in turn upregulates 
transcription factors that stimulate 
lipogenesis. Besides growth of adipose 
tissue, this causes ectopic deposition of 
triglycerides in other tissues such as heart, 
kidney and pancreatic β-cells, where 
nonoxidative metabolism of fatty acids 
produces damaging compounds, resulting 
in functional impairment and apoptosis 
(for review, see Unger & Orci 2001). This 
phenomenon, referred to as lipotoxicity, is 
believed to cause the common 
complications of obesity, insulin resistance, 
cardiovascular disease and diabetes; 
therefore, the obese Zucker rat is 
considered a useful experimental model of 
the human metabolic syndrome (Kasiske 
et al. 1992; Unger & Orci 2001).  
 
Comparison of the presumably monogenic 
disorder of the rat with the polygenic and 
environmentally induced human counter-
part is certainly complex in many ways. 
Lack of leptin action, although such 
mutations have been reported (Clement et 
al. 1998), is not a major causative factor in 
human obesity (Rolland et al. 1998), and 
the whole concept of lipotoxicity in 
humans in this context is somewhat 
controversial. However, regardless of the 
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cause, disproportion between energy 
intake and consumption is the common 
element in the development of obesity in 
both species, and the array of 
complications is surprisingly similar. Thus, 
while more specific models may exist for 
separate studies on hyperlipidemia, 
hypertension, and obesity, the obese 
Zucker rat is one of the few (Chen & Garg 
1999) that seems suitable for examining 
the prevention and treatment of the whole 
syndrome. 
 
In the present study, most serum lipid 
analyses were performed in an accredited 
commercial biochemistry laboratory. 
Before and during the experiments, serum 
total cholesterol was determined by 
reflotron capillary analysis. This system 
was developed for screening purposes in 
humans and has proven fairly fit for that 
use (Statland 1990). It has not been 
previously tested for rats, and could thus 
be unreliable; however, analysis of pooled 
parallel measurements of the present series 
of studies showed an excellent correlation 
between the reflotron and standard 
laboratory values of serum cholesterol (r = 
0.951, p < 0.001, n = 104). 
 
Blood pressure was measured either 
directly by radiotelemetry or indirectly by 
the tail-cuff method. Radiotelemetry is a 
high-fidelity method for 24-hour monitor-
ing of systolic and diastolic blood 
pressures, heart rate, and activity of freely 
moving animals for relatively long periods, 
without the stress of restraints (Bazil et al. 
1993). Major limitations of this method, 
besides its expense, are the need for initial 
surgery, the possible stress caused by 
isolation of the animal, and the few 
months duration of the transmitter 
battery. Also the drifts in telemeter settings 
and sensitivity may cause problems, which 
makes it necessary to recalibrate the 
device immediately before implantation 
(Van Vliet et al. 2000). 
 
The indirect but non-invasive tail-cuff 
method is a more reasonable means for 
measurement of blood pressure, if the 
experiment involves large numbers of 
animals and/or very long time periods. In 
this procedure, the rats must be restrained 
in a heated case to be able to detect the 
pulsations in the tail artery and obtain 
decent blood pressure values. This 
obviously poses a stress factor, which is 
likely to elevate the blood pressure levels, 
although in general the correlations with 
intra-arterial measurements have been 
good (Bazil et al. 1993). Comparability of 
the telemetric and tail-cuff values in the 
obese Zucker rat was also confirmed by 
pilot measurements outside the present 
study (unpublished observation). Stress-
induced fluctuations can be minimized by 
pre-training the animals, by performing the 
measurements regularly by the same 
person in a peaceful environment, and by 
averaging readings from several con-
secutive measurements. One limitation of 
the tail-cuff method is that it only produces 
reliable values for systolic blood pressure. 
 
 
6.2 SERUM LIPIDS 
 
The composition of serum lipids in the 
obese Zucker rat was strongly dependent 
on the fat and mineral contents of the diet. 
Supplementation of a low-mineral diet 
with cholesterol and butter produced up to 
1020 fold increases in serum total and 
LDL cholesterols. Without the butter, the 
increases were less remarkable. A diet 
containing high levels of cholesterol and 
saturated fat is a major cause of elevated 
serum cholesterol also in humans (Sempos 
et al. 1993; Verschuren et al. 1995). 
Saturated fats have long been known to 
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raise serum cholesterol levels, but the 
mechanism of this effect is still not 
completely understood; probably the 
saturated fatty acids inhibit the receptor-
mediated uptake of LDL into liver cells, 
thereby decreasing the clearance of LDL 
particles from the circulation (Kris-Etherton 
et al. 1988; Grundy & Denke 1990). 
 
The most important finding of the present 
study was that supplementation of a high-
cholesterol and high-fat atherogenic diet 
with the combination of plant sterols and 
the mineral nutrients calcium, magnesium 
and potassium effectively lowered serum 
total and LDL cholesterols, and quite 
clearly extended the life span of the obese 
Zucker rats. Part of this effect was 
obviously due to the added plant sterols in 
the diet. The findings of studies IIII, 
where plant sterols were examined 
separately, are consistent with previous 
studies both in animals and in man; they 
have shown that natural plant sterols, or 
their chemically modified derivatives, 
lower serum cholesterol by inhibiting the 
intestinal absorption of cholesterol (Law 
2000; Lichtenstein & Deckelbaum 2001).  
 
However, a significant part of the effect 
can also be assigned to the increased 
content of calcium in the diet. Studies IIII 
that examined the effects of different 
mineral compositions showed that calcium 
and magnesium were not only able to 
lower serum cholesterol but also enhanced 
the effect of plant sterols. In particular, 
dietary calcium intake alone had an 
inverse correlation with serum total and 
LDL cholesterols and, during a low-fat 
diet, even a positive relation with HDL 
cholesterol. These results are in agreement 
with previous studies with calcium 
supplements in experimental (see TABLE 2 
on page 15) as well as clinical studies 
(TABLE 3 on page 17). In compliance with 
previously documented methods (Mietti-
nen et al. 1990), analysis of some serum 
plant sterols and cholesterol precursors 
suggested that calcium dose-dependently 
increased the endogenous synthesis of 
cholesterol, and possibly also its intestinal 
absorption. This apparently paradoxical 
effect can be explained by the concept that 
calcium binds bile acids. Increased fecal 
loss of bile acids is compensated by 
increased conversion of cholesterol to bile 
acids in the liver, which leads to depletion 
of the hepatic cholesterol pool and 
eventually to reduction of serum chole-
sterol levels as well. Thus, the cholesterol-
lowering mechanism of calcium would be 
similar to that of cholestyramine and other 
resins (Witztum 1996). In theory, the 
increase in cholesterol precursor levels 
could also be due to inhibition of the 
enzymes that convert the precursors to 
cholesterol, but there is no indication in 
previous literature of such an action of 
calcium. Another weakness in this 
reasoning is that the findings of Miettinen 
et al. (1990) relate to humans but might 
not be applicable in rats. Nevertheless, the 
present conclusion of compensatory 
increase in cholesterol synthesis is con-
sistent with previous results on treatment 
with other cholesterol-lowering agents 
such as plant sterols (Miettinen et al. 1995; 
Gylling et al. 1999; Jones et al. 2000), 
neomycin (Miettinen 1982) and bile acid 
sequestrants (Strandberg et al. 1990; 
Witztum 1996). In addition to binding bile 
acids, calcium can also reduce the 
absorption of fat by forming insoluble 
soaps with fatty acids (Drenick 1961; 
Welberg et al. 1994). Decreased absorp-
tion of saturated fatty acids could increase 
the clearance of LDL from the circulation 
(Kris-Etherton et al. 1988; Grundy & 
Denke 1990), thereby lowering serum 
LDL cholesterol levels. The fatty acid 
binding action of calcium is likely to 
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contribute to the lowering of serum 
cholesterol, especially during high intake 
of saturated fat. Both of these mechanistic 
views are supported by previous literature: 
increases in fecal fat and/or bile acid 
excretion associated with dietary calcium 
supplementation were reported in several 
animal as well as human studies (see 
TABLES 2 and 3).  
 
Increases in dietary calcium intake also 
enhanced the cholesterol-lowering effect of 
plant sterols, particularly during a low-fat 
diet. In the rats fed the high-fat diets, this 
relationship with calcium was no longer 
dose-dependent; rather, the effect of plant 
sterols appeared most pronounced during 
the low- and moderate-calcium diets. 
Calcium intake in humans is typically 
rather low, and intakes as high as in the 
present study are hardly possible outside 
experimental conditions. Therefore, it is 
important to note that already a moderate 
calcium supplementation with plant sterols 
lowered serum LDL cholesterol almost as 
effectively as the high-calcium diet alone, 
despite the reactive increase of endo-
genous cholesterol synthesis. The increase 
in serum triglyceride levels observed in the 
plant sterol supplemented groups during 
high-fat diets is clearly a disadvantage of 
this combination; however, it might be 
explained by the increased compensatory 
production of lipid-rich VLDL particles in 
the liver.  
 
The increases in serum HDL cholesterol 
(II) and HDL to LDL cholesterol ratios (II
IV) produced by the combination of 
calcium and plant sterols are particularly 
interesting and important, because low 
HDL cholesterol is an independent risk 
factor for atherosclerosis and also a marker 
for the metabolic syndrome (Gotto 2001). 
Elevated levels of HDL cholesterol alone 
and in relation to total and LDL 
cholesterols, accordingly, provide protec-
tion against cardiovascular diseases. This 
effect of HDL has been largely attributed 
to its role in reverse cholesterol transport, 
in which cholesterol that has been 
synthesized or deposited in peripheral 
tissues is returned to the liver. However, in 
view of recent research, the connection 
between lipoproteins is more complex and 
involves specific protein-receptor interac-
tions and activation of cellular signaling 
pathways, which regulate proteins 
involved in platelet activation, thrombosis, 
cell adhesion, apoptosis and vasomotor 
functions (O'Connell & Genest 2001). 
Quite recently, Spieker et al. (2002) 
demonstrated that HDL restores the LDL 
induced endothelial dysfunction, which is 
an early event in the atherosclerotic 
process, in hypercholesterolemic men. 
 
 
6.3 BLOOD PRESSURE 
 
The high-salt, high-cholesterol and high-fat 
atherogenic diet markedly increased blood 
pressures of the obese Zucker rat in both 
telemetric and tail-cuff measurements. This 
is in accordance with previous studies 
pointing to the salt-sensitivity of this model 
(Reddy & Kotchen 1992; Morgan et al. 
1995). Excessive intake of dietary sodium 
is a major cause of hypertension also in 
humans (Kotchen & McCarron 1998). The 
plant sterols and mineral nutrients 
supplemented diet, using a potassium- and 
magnesium-enriched, sodium-reduced 
mineral salt instead of common salt, and 
calcium, completely prevented the 
development of hypertension in this 
model. The same mineral salt has a similar 
effect in another salt-sensitive model, the 
spontaneously hypertensive rat, even 
when dietary sodium content is 
intentionally kept constant (Mervaala et al. 
1992), and it has been shown to lower 
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blood pressure in humans as well 
(Geleijnse et al. 1994; Itoh & Kawasaki 
1998; Katz et al. 1999). The antihyper-
tensive effects of potassium and also 
calcium are well established (Kotchen & 
McCarron 1998). All these mineral 
nutrients appear to facilitate renal sodium 
excretion, although reduction in dietary 
sodium intake is also important, and may 
have contributed to the effects observed in 
the present study as well. 
 
However, not all studies have 
demonstrated any salt-induced rise in 
blood pressure in the obese Zucker rat 
(Pawloski et al. 1992), and a pair-feeding 
experiment indicated that the obese 
hypertensive rats retained even less 
sodium than the normotensive lean 
controls (Kurtz et al. 1989). Thus, other 
mechanisms for the hypertensive effect of 
the atherogenic diet must also be 
considered. Previously, the development 
of hypertension in the obese Zucker rat 
has been associated with the progression 
of renal damage in aging animals (Kasiske 
et al. 1992). In the present study, 
increased albuminuria during the athero-
genic diet (IV) indicated an early 
development of renal damage, whereas 
there was no sign of such damage in the 
plant sterols and mineral nutrients 
supplemented diet group. Renal damage is 
strongly linked to serum lipid profile, in 
both humans and several animal models; 
it has been shown that hyperchole-
sterolemia induces glomerulosclerosis and 
tubulointerstitial damage, and treatment 
with lipid-lowering drugs improves 
glomerular filtration rate and reduces 
albuminuria (Kasiske et al. 1990; Greco & 
Breyer 1997; Fried et al. 2001). In the 
present study, the rise of serum cholesterol 
was almost completely blocked by the 
plant sterols and mineral nutrients 
supplementation, which could at least 
partly explain the protection against renal 
damage and, consequently, the gradual 
development of hypertension. This view is 
supported by the results of the long-term 
experiment (IV), in which the rats on the 
plant sterols and mineral nutrients 
supplemented diet lived much longer than 
the ones on the atherogenic diet, and 
glomerulosclerosis and necroses were 
observed in the kidneys of the rats on the 
atherogenic diet. 
 
Improvement in the endothelium-
mediated vasodilation may also partly 
explain the blood pressure lowering effect 
of the plant sterols and mineral nutrients 
supplemented diet. Previous studies have 
demonstrated that calcium (Pörsti 1991; 
Mäkynen et al. 1996) as well as 
potassium- and magnesium-enriched diets 
(Mervaala et al. 1994; Mäkynen et al. 
1995; Tolvanen et al. 1998) improve 
vascular relaxation and lower blood 
pressure in different rat models. In the 
present study (IV), the relaxation response 
to acetylcholine in a muscular conduit 
artery in vitro was markedly increased by 
the plant sterols and mineral nutrients 
supplemented diet, even beyond the 
control diet group, which may have 
contributed to the protection against the 
prohypertensive components of the diet. 
Because the vascular relaxation responses 
were similar in the atherogenic and control 
diet groups, the endothelial dysfunction as 
such is not likely to be the cause of the 
diet-induced hypertension but rather a 
character of the species, probably related 
to obesity and hyperlipidemia (Wu et al. 
1996; Duarte et al. 1999). As hyper-
lipidemia is known to induce endothelial 
dysfunction (Ross 1999; Kinlay et al. 
2001), the antihypertensive effect of the 
plant sterols and mineral nutrients supple-
mented diet may also be related to the 
lipid-lowering action of the combination.  
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6.4 OBESITY 
 
In agreement with previous reports (Zucker 
1965; Kurtz et al. 1989; Kasiske et al. 
1992) the Zucker rats developed 
pronounced obesity with marked accumu-
lation of subcutaneous and abdominal fat 
during the control and atherogenic diets. 
Enrichment of the high-fat diets with the 
plant sterols did not affect weight gain. 
However, enrichment of the high-fat diets 
with calcium (and magnesium), both in the 
absence and in the presence of plant 
sterols, induced a marked reduction in the 
development of obesity. In the first study, 
the compositions and possibly also the 
taste of the diets were quite different, and 
the rats might have eaten less and 
therefore lost weight in the beginning of 
the study. In the other studies, however, 
body weight gain was monitored more 
carefully, and the diets were made as 
similar as possible so that even the 
chloride concentrations were adjusted to 
the same level, and still the difference 
persisted. These findings are concordant 
with previous studies of calcium supple-
ments in other rat strains (Fleischman et al. 
1967; Yacowitz et al. 1967; Foley et al. 
1990; Pörsti et al. 1990; Mäkynen et al. 
1996). 
 
In the long-term study, body weight 
remained slightly lower in the plant sterols 
and mineral nutrients supplemented rats 
until about six months, after which the rats 
on the atherogenic diet started losing 
weight, obviously due to enervating 
disease processes. While these rats were 
dying, the others kept on thriving for 
another six months and some of them 
eventually weighed more than 800 g. In 
this view body weight per se did not seem 
to be a very important factor in longevity. 
However, the initial better weight control 
in the plant sterols and mineral nutrients 
supplemented diet group may partly have 
delayed the disease processes, thus 
contributing to the general well-being and 
reduced mortality. In humans, even a 
small weight reduction is associated with 
favorable changes in blood pressure, 
serum lipids and glucose metabolism and, 
thus, reduction in the risk of diabetes and 
heart disease (Anderson & Konz 2001).   
 
The slower increase of body weight in the 
calcium-supplemented groups of the 
present studies appeared to be due to 
reduced accumulation of fat tissue, 
because the calculated lean or skeletal 
body weight was not affected, and 
because urinary creatinine excretion, used 
as an indicator of muscle catabolism, was 
not changed. Also the estimated food and 
energy intakes were equal in the different 
dietary groups, or in some cases, even 
higher in the calcium-supplemented 
groups than in the other groups. 
Therefore, the reduction in the amount of 
fat tissue appears to be due to increased 
loss rather than decreased intake of 
energy. A plausible mechanism would be 
the formation of insoluble soaps of fatty 
acids and the divalent cations calcium and 
magnesium in the intestine (Drenick 1961; 
Welberg et al. 1994), leading to reduced 
absorption of fatty acids so that part of the 
ingested energy is lost into stools. This 
view is largely supported by previous 
studies with calcium supplements (see 
TABLES 2 and 3), with or without any 
reported body weight effects; it must be 
noted that a reduction in fat absorption 
does not necessarily lead to any reduction 
in fat accumulation, if food intake is not 
controlled. Previous studies have also 
demonstrated improvements in carbo-
hydrate metabolism by increased intakes 
of potassium and magnesium (Rapoport & 
Hurd 1964; McFarland & Carr 1977; 
Karppanen et al. 1984; Paolisso et al. 
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1989; Balon et al. 1995). In the present 
study, the serum insulin to glucose ratio 
was most markedly decreased in the 
potassium and magnesium enriched diet 
groups, suggesting an improvement in 
insulin sensitivity, although the possibility 
that this difference was due to the 
decreased amount of carbohydrates in the 
diets cannot be excluded. Furthermore, 
calcium may affect fat metabolism and the 
control of energy balance. Zemel et al. 
(2000) have shown that increased 
circulating levels of the calcitrophic 
hormones PTH and vitamin D during low-
calcium diets increase cellular calcium 
influx, which in turn stimulates lipogenesis 
and inhibits lipolysis in adipocytes. 
Accordingly, increased dietary calcium 
intake would suppress these calcitrophic 
hormones and thereby reduce the 
adipocyte intracellular calcium and lipid 
storage. The PTH or vitamin D status of 
the rats was not assessed in the present 
study. However, in obese mice calcium 
supplementation has been reported to 
lower the levels of these hormones and 
reduce lipid accumulation and body 
weight (Shi et al. 2001). In humans, high 
intake of calcium is associated with 
decreased parathyroid function (McKane 
et al. 1996), and even acute ingestion of 
calcium is followed by a significant 
decrease in serum PTH level (Tohme et al. 
1990). Involvement of dietary calcium in 
the physiological regulation of body weight 
and adiposity is also indicated by some 
epidemiological (McCarron et al. 1984; 
Zemel et al. 2000; Carruth & Skinner 
2001) as well as clinical studies (Davies et 
al. 2000).  
 
6.5 HUMAN  IMPLICATIONS 
 
Hyperlipidemia, hypertension, obesity and 
type II diabetes are strongly interrelated 
conditions and form a serious health 
hazard particularly to modern western 
populations. Dietary and lifestyle factors 
are most important causes behind these 
risk factors; therefore, it would be 
reasonable to look for dietary approaches 
for their modification. Reduced intake of 
sodium and increased intakes of calcium, 
magnesium and potassium have proven 
antihypertensive in several studies in 
humans, and are currently recommended 
for even the general population by health 
organizations and officials worldwide 
(Joint National Committee 1997; Kotchen 
& McCarron 1998; Krauss et al. 2000). 
Furthermore, calcium is considered impor-
tant in prevention of some other chronic 
diseases, primarily osteoporosis (Miller & 
Anderson 1999). Plant sterols and stanols 
are also recommended and useful for 
lowering of elevated blood cholesterol 
levels (Law 2000; Lichtenstein & Deckel-
baum 2001). The DASH study, in particu-
lar, has shown the practical relevance of 
combination diets low in sodium, fat and 
cholesterol, and high in calcium, magnesi-
um, potassium and plant fiber in treatment 
of elevated blood pressure (Appel et al. 
1997; Sacks et al. 2001) and even in 
lowering serum lipid levels (Obarzanek et 
al. 2001). Quite recently, the first clinical 
trial confirmed the cholesterol-lowering 
effect of food items prepared according to 
the principles described in the present 
experimental study (Tikkanen et al. 2001). 
Further research in humans would appear 
warranted to find out if a long-term use of 
foods enriched with this kind of 
combination of mineral nutrients and plant 
sterols is able to produce any of the other 
beneficial effects that were seen in the 
obese Zucker rats. 
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7 SUMMARY AND CONCLUSIONS 
 
 
 
 
The purpose of this study was to investigate the effects of mineral nutrients and plant 
sterols on serum lipids, blood pressure and body weight in an experimental model of 
obesity and the metabolic syndrome, the Zucker rat. The findings and conclusions are as 
follows: 
 
1. The combination of plant sterols and the mineral nutrients calcium, magnesium 
and potassium prevented the diet-induced rise of serum cholesterol more 
effectively than either the plant sterols or the minerals alone. Dietary 
supplementation of the mineral nutrients reduced body weight, both in the 
presence and in the absence of plant sterols. 
 
2. The combination of plant sterols with sodium and potassium did not provide any 
cholesterol- or body weight-lowering effects beyond that of plant sterols alone, 
whereas the combination of plant sterols with calcium and magnesium both 
prevented hypercholesterolemia and markedly reduced the accumulation of excess 
body fat. 
 
3. Dietary calcium lowered serum total and LDL cholesterols in a dose-dependent 
manner, and increased the HDL to LDL cholesterol ratio both during low-fat and 
high-fat diets. These effects were partly enhanced by concurrent plant sterol 
supplementation. Moreover, high levels of dietary calcium reduced obesity, 
independently of plant sterols. The effects of calcium are likely to be mediated by 
inhibition of the intestinal absorption of saturated fat and bile acids. 
 
4. Long-term supplementation of an atherogenic diet with plant sterols and 
replacement of sodium partly with the minerals calcium, magnesium and 
potassium effectively prevented the diet-induced increases in total and LDL 
cholesterol and 24-hour systolic and mean blood pressure, improved endothelium-
mediated vasodilation, protected against end-organ damage, and considerably 
extended the life span of the obese Zucker rats. 
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